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Racial Disparities in Breast Cancer Surgical Treatment and  
Radiation Therapy Use 
 
Tracey Lynn Koehlmoos 
 
ABSTRACT 
 
This study explores the relationship between race and surgical treatment and 
radiation therapy use for localized breast cancer patients in the state of Florida in 2001. 
The study will be useful in raising awareness of the relationship between Black race and 
appropriate breast cancer treatment within the Florida Cancer Data System. The Healthy 
People 2010 initiatives’ call to eliminate racial disparities and the high placement of 
breast cancer on the national research agenda make this study timely and insightful for 
health policymakers, clinicians and other health researchers. Also, the study evaluates the 
effect of other health system and patient related factors such as insurance provider and 
rural versus urban residence, to the appropriate use of cancer therapy in order to present 
an up-to-date and accurate picture of the quality of breast cancer care for women in the 
state of Florida. 
The study used multivariate logistic regression modeling and chi-square 
distribution to compare models in order to disentangle the effects of age, rural residence, 
marital status and primary health insurance provider from race and to determine how 
these factors influenced breast conserving surgery versus mastectomy use.  Further, the 
second research question exclusively focused on the population that received breast 
conserving surgery in order to examine the impact of race and the other covariates as 
explanatory measures of appropriate receipt of radiation therapy. 
viii 
The first hypothesis found that there was no statistically significant difference 
between Black and White women in terms of receipt of breast conserving surgery for 
treatment of localized breast cancer. The second hypothesis, which focused on 
appropriate receipt of radiation therapy following breast conserving surgery, found that 
there was a statistically significant interaction between Black race and Medicaid as 
primary health insurance provider. 
The study concludes by examining possible areas of improvement in data 
collection in the State of Florida. Also, the study contains recommendations as to 
previously unexplored facets of breast cancer research and breast cancer health policy 
that could be beneficial in the reduction of health and healthcare disparities in other 
geographic areas and in other diseases. 
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Introduction 
The disparity between Black and White women in terms of incidence and mortality from 
breast cancer is well documented.  Over the last twenty years the racial disparity in 
mortality has continued to increase. The difference between the two groups was first 
recorded in 1981 when medical advances in breast cancer treatment dramatically 
increased breast cancer survivability disproportionately for White women (Brawley  471, 
Ries  1998).  The federal Healthy People 2010 initiative established the goal of 
eliminating racial and ethnic disparities in six major areas, including cancer.  (U.S. 
Department of Health and Human Services 2000a).  Recent declines in overall breast 
cancer mortality and increases in screening use and survivability over the last ten years 
masks the plight of the medically underserved and minority populations (Shingawa  
2000).  This study examined an important component of the Black/White racial 
disparities in breast cancer treatment based on the appropriate receipt of breast 
conserving surgery (BCS) with radiation therapy (RT). 
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Statement of the Problem 
Defining Disparities 
In 2003 the Institute of Medicine (IOM) published a comprehensive study which 
demonstrated that "racial and ethnic minorities received a lower quality of healthcare 
than non-minorities, even when access-related factors, such as patients' insurance status 
and income, are controlled" (Institute of Medicine  2003).  The essential message of this 
report was that the health of the individual cannot be separated from the health of the 
larger community and from the health of the state and the nation. The term disparities can 
be defined in a number of ways. The IOM study defined disparities as racial or ethnic 
differences in healthcare that were not due to access-related factors or clinical needs, 
preferences, and appropriateness of intervention (IOM 2003 p.32). The Centers for 
Disease Control and Prevention (CDC) applied a different definition of how it measures 
disparities for the purpose of monitoring the Healthy People 2010 objectives.  The 
principal measure of disparity was a relative measure, the percent difference. The 
difference was measured from the "best" or most favorable group rate, which was not 
always the rate for White, Non-Hispanics. The CDC expressed difference measured for 
indicators in terms of adverse outcomes not favorable outcomes.  For example, the 
percent of people without health insurance rather than the percent with health insurance 
(Keppel 20 February 2004).  Last, the Department of Health and Human Services 
(DHHS) used a broader definition of disparities: 
In the absence of consensus on the definition of disparities, this report [The 
National Healthcare Disparities Report] will focus on presenting the facts.  Where 
3 
we find variation among populations, this variation will simply be described as a 
“difference.”  By allowing the data to speak for themselves, there is no 
implication that these differences result in adverse health outcomes or imply 
moral error or prejudice in any way (DHHS  2003  p.11-12). 
 
Racial disparities in healthcare can be seen on a myriad of levels including 
ethical, public health, justice, economic and is indicative of flaws in the overall quality of 
healthcare.  Policymakers and healthcare providers alike must recognize that disparities 
exist and hamper efforts to improve social justice and national quality of life.  The United 
States is poised to become populated by close to 50% of what is currently considered 
minority group members by 2050 (U.S. Bureau of the Census  2000). 
In 2001, African-Americans had a 33% higher risk of dying from all types of 
cancer than non-Hispanic, Whites. Shavers and Brown (Figure 1) developed a framework 
in order to conceptualize the potential barriers to the receipt of optimal cancer treatment.  
The framework was constructed around structural, provider and patient related factors 
that can negatively influence an individuals treatment options for all types of cancer. 
  
STRUCTURAL BARRIERS PHYSICIAN CLINICAL/FACTORS PATIENT FACTORS 
Health insurance status Physician Recommendation Socioeconomic status 
 
Type of health insurance --Clinical Stage Patient preferences/decision 
making 
 
Type of institution where care 
is received 
 
--Other clinical prognostic indicators Cost/Copayment 
Geographic region where care 
is received 
 
--Co-morbidity Transportation 
 --Pain assessment Time required for treatment 
 
 --Physician perceptions/biases Family/Other support 
Note.  Shavers 2002 
 
Figure 1.  Conceptual Framework: Potential Barriers to Cancer Treatment 
 
 
Disparity Reduction 
During the 1990's numerous programs were developed to attempt to reduce 
overall breast cancer mortality as well as reduce the racial/ethnic and socioeconomic 
disparities in breast cancer mortality.  Governmental policy changes and additional 
funding for programs like the Breast and Cervical Cancer Mortality Prevention Act of 
1990 (Public Law 101-354) covered screening but not treatment of breast cancer through 
the Centers for Disease Control and Prevention's (CDC) National Breast and Cervical 
Cancer Early Detection Program (NBCCEDP).  In order to bridge the screening/treatment 
gap, Congress approved the Breast and Cervical Cancer Treatment and Prevention Act of 
2000, which appropriated $900 million over 10 years to provide treatment for women 
diagnosed with cancer via the NBCCEDP.  As a social equalizer, NBCCEDP has the 
ability to qualify indigent and otherwise uninsured women for breast cancer treatment via 
state administered Medicaid programs.  As of 2002 was available in every state and five 
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tribal areas except Oklahoma (CDC 2003). Another program, the Mammography Quality 
Standards Act (MQSA) of 1992 sought to regulate the quality of mammography 
equipment, but failed to assure the accuracy of interpretation or the effectiveness of post-
screening follow-up. (Bickell 2002).  However, these programs do nothing to guarantee 
or measure the effectiveness or appropriateness of breast cancer treatment.  Figure 2 
presents a timeline of major health policy initiatives that sought to increase access to and 
monitor quality of care in breast cancer screening and treatment. 
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NBCCEDP 
active in 49 
states, 8 
territories, DC 
and all Native
American tribal 
areas  
Mammography 
Quality 
Standards Act 
(MQSA)  
Breast and 
Cervical Cancer 
Treatment and 
Prevention Act 
(NBCCEDP)  
Breast and 
Cervical 
Cancer 
Mortality 
Prevention 
Act   
Figure 2.  Breast Cancer Policy Timeline 
 
In the new millennium breast cancer remains the second leading cause of cancer 
death for Black women in the United States, and the mortality rate for Black women from 
breast cancer is higher than it is for White women despite the lower incidence rate. 
Because of the later stage at which breast cancer is typically diagnosed in Black women, 
5 
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the five-year survival rate for Black women remains significantly lower than for White 
women (75% vs. 88%) (American Cancer Society 2003).  
Breast Conserving Surgery 
Numerous prospective, randomized clinical trials in the United States and in 
Europe during the 1980's demonstrated that survival after BCS was equal to survival after 
mastectomy (Fisher 1989, Blichart-Toft 1988, Veronesi 1981, Sarrazin 1989, Licter 
1992, Van Dongen 1992).  This strong evidence led a 1990 National Institutes of Health 
consensus panel to determine that breast conservation treatment is an appropriate method 
of primary therapy for the majority of women with localized breast cancer (NIH 1992).  
Breast Conserving Treatment (BCT) is defined as the excision of the primary tumor and 
adjacent breast tissue followed by radiation therapy. Breast Conserving Treatment is not 
an option for every case of breast carcinoma. However, the National Cancer Data Base 
issued a report in 1994 that concluded that up to 75% of diagnosed cases of breast cancer 
can be considered localized, thus eligible for BCT (Osteen 1994).  Based on the 
guidelines released in 1992 by an interdisciplinary group which consisted of represented 
the American College of Surgeons (ACoS), American College of Radiology (ACR), the 
College of American Pathologists (CAP), and the Society of Surgical Oncology, there are 
only four absolute exclusion factors against the use of Breast Conserving Therapy. The 
four contraindications are listed below: 
●  Patient in the first or second trimester pregnancy 
●  History of therapeutic irradiation to the breast region 
●  Multiple primary tumors in separate quadrants of the breast 
●  Extensive indeterminate or malignant-appearing calcifications throughout the 
breast (Winchester 1992). 
7 
Need for the Study 
Considering that Black women have a significantly worse prognosis from breast 
carcinoma compared to White women, even when stage at diagnosis is equivalent, it is 
worthwhile then to analyze racial differences in the treatment of women with early stage 
breast cancer as a measure of quality of care (Joslyn 2002, Roetzheim 2000).  That there 
was no recorded difference in breast cancer survivability before 1981 led to the 
hypothesis in many research articles that advances in breast cancer treatment were only 
benefiting one segment of the population (the primarily White, upper and middle classes) 
leaving less adequate care for poor and minority women  (Diehr 1989, Boyer-Chammard 
1999, Breen 1999).  Health care for medically underserved populations remains a high 
priority for the U.S. government.  Particular interest has been paid to cancer care because 
it is both common and expensive, and requires a complex interaction between patients, 
providers and the health care system (Hewitt 1999). 
Breast cancer is firmly entrenched on the national cancer research agenda because 
of its enormous impact on society (Jones 2002, NCI 2001).  This study describes the 
impact of race on appropriate receipt of surgical treatment and radiation therapy for 
localized breast cancer. Results of this study provide policy makers, health researchers 
and health agencies with an assessment of the degree to which Florida has progressed 
toward adoption of breast conserving surgery and radiation therapy for the treatment of 
Early Stage Breast Cancer.  Also, the study demonstrates the effect of other health system 
and patient related factors such as insurance provider and rural versus urban residence, to 
the appropriate use of cancer therapy in order to present an up-to-date and accurate 
picture of the quality of breast cancer care for women in the state of  Florida. 
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Review of the Literature 
In the 13 years since the NIH report, there continues to be an underused of BCT 
as a less radical alternative to mastectomy for treatment of local stage breast cancer 
despite increases in the detection.  The average BCS rate for the United States remains 
very low with only 40-50% of eligible patients undergoing the less invasive procedure 
(Morrow 2001, Lazovich 1999).  Mastectomy rather than BCS remains the primary 
surgical approach to treating local breast cancer in many geographic regions.  Patient 
advocacy groups, researchers, clinicians and policymakers consistently argue that BCS 
plus radiation is superior for most women because it is less invasive, preserves the breast, 
and post-surgical psychological adjustment is less difficult (Lantz 2002).  Considering 
that Black women have a significantly worse prognosis from breast carcinoma compared 
to White women, even when stage at diagnosis is equivalent, it is worthwhile then to 
analyze racial differences in the treatment of women with early stage breast cancer as a 
measure of quality of care (Joslyn 2002, Roetzheim 2000). 
Use of Breast Conserving Surgery 
Overall studies of breast cancer surgery using race/ethnicity as a predictive 
variable have produced conflicting results.  Several studies from the 1990's reported that 
breast cancer treatment differed between African-American women and White women 
but there is wide variation among researchers as to the perceived cause of the difference.  
National data from the early 1990's show that Black women were less likely to undergo 
BCS than white women (Muss 1992).  Nattinger and associates and Johantgen and 
9 
associates found that surgical treatment varied even after adjusting for breast cancer stage 
at diagnosis (Nattinger 1992, Johantgen 1995).  More recently articles by Newman and 
associates and Velanovich and associates demonstrate that Black women continue to be 
less likely than White women to undergo BCS.  However, the latter two studies focused 
on a limited population within the same urban area (Newman 1999, Velanovich 1999).  
Also, the Carolina Breast Cancer Study from 1995 through 2000 showed that fewer Black 
women received BCS than White women (Dunmore 2000). 
On the other side of the spectrum, in 2002 Joslyn released a study that analyzed 
SEER program data from 1988-1998 which found that Black women were slightly more 
likely the receive BCS than White women, but the differences were not clinically 
significant; however, greater than one-third of the Black women were premenopausal 
compared with fewer than one-fourth of White women (Joslyn 2002).  Other studies 
showed that after adjusting for sociodemographic information that race was not a 
significant indicator of type of surgery used to treat breast cancer. Using data from the 
Surveillance, Epidemiology, and End Results (SEER) national tumor registry program, 
Gilligan and associates show that from 1983-1996 the use of BCS increased consistently 
across all racial groups and that when researchers adjust for socioeconomic covariates 
such as county level of education and county income, race proved not to be a significant 
indicator of the use of BCS (Gillligan 2002). 
In addition, a study of California, New Mexico and Detroit, Michigan breast 
cancer cases from 1992-1995, Richardson and associates found that once they had 
adjusted for stage of disease at diagnosis, there was no significant difference in surgical 
treatment (Richardson 2001).  Bradley and associates in a different study of the Detroit, 
10 
Michigan area that linked SEER program and Census data found that when controlling 
for age, race, marital status, cancer stage, Medicaid status, and census tract poverty level, 
Black women were statistically significantly as likely as White women to receive BCS. 
However, within the Medicaid population, Black women were more likely to receive 
BCS than White women, were when not adjusting for health insurance, Black women 
were overall less likely to receive any form of breast cancer surgery than White women 
(Bradley 2002). Bradley cautions that although poverty presents itself as the strongest 
indicator of poor cancer stage of diagnoses, treatment and death, the fact remains that 
Black women are more likely to have lower incomes and live at or below the poverty 
level than White women. 
Using data from 1997 and 1998, Luther and Studnicki related physician volume to 
the use of mastectomy versus BCS. In contrast to the aforementioned Bradley study, 
Luther found that Medicaid insured women were significantly less likely to receive BCS.  
Although BCS had become the most common form of breast cancer surgical treatment, 
they found that in Florida non-whites were more likely to be treated by low volume 
surgeons who were more likely to perform mastectomies; whereas White women and 
privately insured women were more likely to receive BCS (Luther 2001). However, this 
study grouped all non-white cases into one category which can bias study results toward 
the null in that non-white Hispanic, Native American, and Asian racial and ethnic groups 
tend to vary widely from Black women in their cancer outcomes and sociodemographic 
factors (Bradley 2002). 
In another Florida-based breast cancer study using data from 1994, Roetzheim 
and associates found there was no racial differences in the use of BCS although insurance 
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type varied greatly by race/ethnicity. Black women constituted 6.9% of the study 
population yet had a higher risk of being covered by Medicaid (6.6% for Black v. 1.8% 
for White women) or to be uninsured (10.0% for Non-White women v. 3.6% for White 
women) (Roetzheim 2000). 
Use of Radiation Therapy 
Similar to the divergent findings for the use of breast conserving surgery, research 
conducted on the use of radiation therapy has produced equivocal results.  Radiation 
therapy (RT) is the factor that makes Breast Conserving Therapy a definitive primary 
treatment for women undergoing breast conserving surgery.  In addition to race, 
advanced age (75+ or 80+ years of age, depending on the study), becomes a variable of 
interest in the receipt of appropriate post surgical radio therapy.  The incomplete use of 
breast conserving therapy (BCS + RT) in any one group based on age, race or residence 
is in conflict with the NIH Consensus Statement and raises quality of care issues 
(Gilligan 2002). 
In a 1992 study of geographic variation in the treatment of localized breast cancer 
that used SEER program data, Farrow and associates found that older women across the 
United States and Black women in the Atlanta and Detroit areas were significantly less 
likely to receive RT following BCS.  The radiation use decreased initially after age 65 
and more steeply after age 75 (Farrow 1992).  Similarly, Ballard-Barbash found that 
frequency of radiation therapy did not vary significantly by racial group; however it did 
increase in areas with higher educational levels and decrease significantly with each five-
year age group (Ballard-Barbash 1996).  In addition studies by Roetzheim and associates 
and Marrow and associates see no racial disparity for radiation therapy based on race, but 
12 
rather by age (Marrow 2001, Roetzheim 2000).  Using NBCCEDP linked data from three 
Western states, Richardson and associates also found no association between 
race/ethnicity and the receipt of RT (Richardson 2001).  
On the other hand, Bradley and associates found that Black women were less 
likely to receive radiation following BCS than white women (OR .74, 95% CI: .61-.88). 
However, when logistic regression models controlled for poverty via residence in a 
census tracts with poverty levels of 13% or greater, age, race, marital status, cancer stage 
and Medicaid status, Bradley found that Black women did not have a statistically 
significant difference in the use of radiation therapy after breast conserving surgery. 
(Bradly 2002).  In a ten-year, national study using SEER data, Joslyn found that 29.9% of 
Black women versus 24.2% of White women in the study did not receive radiation 
therapy post-BCS.  Black women were significantly less likely to receive radiation at 
each age category except the group of 85years of age or older (Joslyn 2002). 
Additionally, there are access issues created by distance to radiation facilities that 
may serve as barriers to appropriate use of radiation therapy for post-breast conserving 
surgery cases.  The availability of transportation and the relative convenience of such 
facilities may also account for slower rates of adoption of breast conserving therapy 
versus modified radical mastectomy for early stage breast cancer (Nattinger 2001).  
Nattinger’s study found that women living more than 15 miles from a hospital with a 
radiotherapy center had a significantly reduced likelihood of undergoing BCT (OR .52, 
CI 0.46-0.58).  Parviz and associates used geocoding software to examine the effect of 
distance from home to therapy site on initial surgical treatment and found that there was 
no statistically significant difference in BCT rates when looking at distance as a 
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continuous variable.  However, statistical significance existed when cases were 
categorized dichotomously based on greater than or less than 40 miles from the radiation 
therapy center.  Weaknesses of the Parviz study include that it was conducted on a small 
sample size treated by the same team of surgeons at the same teaching facility (Parviz 
2003).  In a U.S. wide study conducted in 2002, Gilligan found that there was greater use 
of breast conserving surgery and radiation therapy in urban areas compared to rural areas 
(Gilligan 2002). 
Study Contribution to the Literature 
The state of Florida presents itself as the ideal setting in which to undertake this 
study.  Florida has the highest crude incidence rate of cancer in the nation with a 
14,000,000 population residing in 67 counties.  Two hundred forty-seven hospitals report 
over 120,000 cases annually, which when unduplicated, translate into approximately 
80,000 newly diagnosed cases per year (FCDS 2003).  With both a large elderly 
population and a large minority representation, Florida is a bell-weather state for the 
graying population of the entire United States.  In Florida in 2001, there were 18,403 
incident cases of breast cancer out of 103,587 analytic, incident all-type cancer cases 
(FCDS Monograph 2003). 
This study will contribute to the vast body of breast cancer research by providing 
an up-to-date picture of the breast cancer treatment differences or lack of differences 
between Black and White women in Florida for both surgical options and the appropriate 
use of radiation therapy post-breast conserving surgery.  Also, this study will differ from 
other studies by adjusting for and evaluating the influence of rural versus urban residence 
14 
in the use of surgical option and radiation therapy by employing the new continuum 
developed by the United States Department of Agriculture (USDA 2003). 
Limitations 
Limitations are factors outside of the researcher's control that can affect the 
outcome of the study. Several limitations exist within this study design.  The choice to 
conduct secondary data analysis is beneficial in many ways (economic cost, scope of 
sample size) but can hinder a researcher in terms of limiting the ability to select variables 
to be included in multivariate modeling.  There is a necessary gap between the type of 
data the researcher would like to collect for inclusion in the study and the information 
that is available in the pre-existing dataset (Iezzoni 2003, Nachmias & Nachmias 1998). 
Additionally, the use of the Florida Cancer Data System tumor registry 
information inherently imposes several limitations.  The registry only includes cancer 
cases treated within Florida and may limit the generalizability of findings to other states 
or regions of the country.  When using a coded data source the issue of reliability 
revolves around how accurately and completely the coded information from the medical 
records was abstracted. 
Last, the validity of using cancer registry data for evaluating quality of cancer 
care has not been well studied.  Malin and associates compared medical records, the 
"gold standard," to California Cancer Registry data and found that the validity of registry 
data varied across the settings of care.  As cancer care moved from the in-patient setting 
the capture of data decreased as follows:  surgery, radiation therapy, chemotherapy and 
hormonal therapy.  Thus, although registry data may be valid for use in studying surgery 
and radiation therapy, it is not equally valid for studying the use of chemotherapy and the 
15 
prescription of adjuvant therapy (like Tamoxifen) which are more likely to take place in 
an ambulatory setting or physician's office (Malin 2002). 
Hypotheses 
Hypothesis One.  Black women in Florida are statistically significantly less likely 
than White women to receive breast conserving surgery rather than mastectomy for 
treatment of localized breast cancer.  
Hypothesis Two.  Black women in Florida are statistically significantly less likely 
than White women to receive radiation therapy after breast conserving surgery. 
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Research Design 
Data Source 
This study proposes to answer the above hypotheses by conducting secondary 
data analysis using the Florida Cancer Data System information from the year 2001.  
FCDS is Florida's Statewide Population-Based Cancer Registry. The result of a 
collaboration between the Florida Department of Health and the Sylvester 
Comprehensive Cancer Center (SCCC) at the University of Miami School of Medicine 
designed and implemented the registry in 1978.  FCDS has been collecting incidence data 
since 1981.  
In October 1994, the Florida Cancer Data System became part of the National 
Program of Cancer Registries (NPCR) administered by the Centers for Disease Control 
(CDC).  Through this program the CDC provides funding for states, such as Florida, to 
enhance their existing registry to meet national standards for completeness, timeliness 
and data quality set forth by the North American Association of Central Registries 
(NAACCR), the American College of Surgeons, Commission on Cancer (ACoS/CoC) 
and the Surveillance, Epidemiology and End Results (SEER) reporting program of the 
National Cancer Institute (NCI). 
The legal statutes that govern the creation of the database and the participation of 
facilities providing cancer care are numerous.  Florida Statute 385.202 provides for the 
establishment of a statewide cancer registry.  All facilities licensed under Florida Statute 
395 and each freestanding radiation therapy center as defined in Florida Statute 408.07 
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shall report to the Department of Health, through FCDS, such cancer incidence 
information as specified by Rule 64D-3.006, which includes, but is not limited to, 
diagnosis, stage of disease, medical history, laboratory data, tissue diagnosis, radiation, or 
surgical treatment and either method of diagnosis or treatment for each cancer diagnosed 
or treated by the facility or center. 
Confidentiality 
FCDS continues to adhere to all Florida Statues and Department of Health 
guidelines regarding patient and institutional confidentiality.  No unique, patient 
identifying information will be used in the conduct of this study. 
Approach 
First univariate analysis describing the characteristics of the population was 
conducted. This included unadjusted mean values of continuous variables and frequency 
analysis of categorical variables.  The results of the univariate analysis are given in tables 
in the Results chapter.  Next, bivariate analysis was conducted to describe the 
relationship between the predictor variable of interest, Race, and each of the covariates.  
Next, two separate, multivariate logistic regression models were developed.  Logistic 
regression is typically used to model dichotomous dependent variables and performs well 
when compared to more complex modeling approaches (Feinstein, Wells and Walter 
1990, Selker 1995, Iezzoni 2003).  The first model dealt with the outcome/dependent 
variable of type of surgery and race, and the second model evaluated the recommended 
use of radiation therapy and race.  A description of the variables used in the study is 
provided below. 
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In developing the models an iterative process of determining which of the 
covariates are useful to the explanation of the dependent variable was followed.  Model 
fit statistics were used and interaction terms were evaluated for inclusion.  All models 
were developed first to determine unadjusted odds ratios and, next, refined to determine 
adjusted odds ratios.  Also, to remain consistent with the literature, the conventional, 
nominal levels for alpha, p-value less than or equal to 0.05, and ninety-five percent 
confidence intervals were developed in order to determine statistical significance of study 
results.  These results are presented in the next chapter using a variety of tables.  Finally, 
all multivariate logistic regression modeling was performed using SAS version 8.00 for 
Windows (SAS Institute, Cary, NC). 
Inclusion and Exclusion Criteria 
Initially localized breast carcinoma cases occurring in women reported to the 
Florida Cancer Data System during 2001 will be considered for inclusion in this study.  
Additional inclusion and exclusion criteria are detailed below. 
Gender.  Men and women differ chromosomally, anatomically, physiologically, 
hormonally and reproductively.  Socioeconomic circumstances influence the lives of the 
two genders differently (Iezzoni 2003).  Breast cancer is 100 times more likely to occur 
in women than in men, yet each year in the United States about 400 men die of breast 
cancer (0.22 percent of all cancer deaths).  Because of the small size of men's breasts and 
location of the primary tumor is most frequently in the center of the breast, modified 
radical and radical mastectomy are the most common surgical options for men.  Because 
of the differences in surgical treatment (outcome variable) and because male breast 
cancer is a rare disease, men are excluded from the study (Elk 2003).  Additionally, 
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subjects coded as "Intersexed," "Transgendered" or "Unknown" are also excluded from 
the sample.  Thus, only subjects coded as "Female" will be included in the data set to be 
analyzed for the study. 
Stage of disease. The disease to be studied exclusively in this study is breast 
cancer.  The initial data set to be examined will be all breast cancer cases within the 
FCDS for 2001 (coded as C50.0-C50.9).  Iezzoni writes that research targeting one 
particular disease will not need to adjust for the presence of the disease but rather for the 
disease specific severity (Iezzoni 2003).  
Recent long-term randomized clinical trials have reaffirmed that breast 
conserving surgery is appropriate for women with local stage breast cancer (Fisher 1995, 
Veronesi 1995).  Rather than recording American Joint Commission on Cancer staging 
information, the FCDS reports SEER Summary Stage information listed in Table 1.  
 
Table 1 
 
SEER Summary Stage 
Code Description 
0 in situ 
1 Local 
2 Regional/Direct Extension 
3 Regional/Nodes Only 
4 Regional/Direct Extension and Nodes 
 
 
SEER Summary Stage is based on a combination of pathologic, operative and 
clinical assessments. The Summary Stage in the FCDS data set is based on all 
information available through completion of surgery in the first course of treatment or 
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within four months of diagnosis in the absence of disease progression, whichever is 
longer (FCDS-DAM 2003). 
For the purpose of answering Hypotheses #1 and #2, only women with Local 
stage breast cancer, which includes lymph node-negative findings will be included in the 
analysis (Farrow 1992, Roetzheim 2000, Richardson 2004). 
Missing Values 
Cases with missing variables will not be included in analysis because such 
missing variables may produce biased results.  This common approach for dealing with 
subject records in a data file that are incomplete is called complete-subject analysis.  
However, there is the potential to lose statistical power should a significant number of 
any variable be missing from the data set or be more likely to be missing from one 
category.  Thus, there may be the need to re-evaluate the inclusion of cases with missing 
information (Rothman 1998).  If there are differences in the pattern of missing variables, 
Tabachnick and Fidell recommend five methods of dealing with the variables:  1) delete 
the cases or variable; 2) estimate the missing data using a mean value; 3) use a missing 
data correlation matrix; 4) treat missing data as data; and 5) repeat analyses with and 
without missing data (Tabachnick 1989). 
Dependent (Outcome) Variables 
Surgery type.  Surgery type will be categorized as a dichotomous variable. In the 
comparison of Mastectomy versus Breast Conserving Therapy, BCS will be defined as 
lumpectomy, segmental mastectomy, quadrantectomy, tylectomy, wedge resection, 
nipple resection, excisional biopsy, and partial mastectomy not otherwise specified.  BCS 
may or may not have included axillary lymph node dissection and/or follow-up radiation. 
Mastectomy will be considered as simple and subcutaneous mastectomies, radical 
mastectomies and modified radical mastectomies.  Surgical procedures within the data set 
are coded using SEER program and COC/ACoS surgery identifiers (FCDS-Data 
Acquisition Manual Appendix H 2003).  The surgical codes are divided into two possible 
groups (0/1) as previously described.  Although the FCDS includes categories for "No 
Surgery," "Surgery, Not Otherwise Specified," and "Unknown," cases with those entries 
in the Primary Surgery Summary field of the database will be excluded from this study. 
Radiation Therapy.  Radiation Therapy will be collapsed into a dichotomous 
variable.  The FCDS defines Radiation Therapy as listed below in Table 2. 
 
Table 2 
 
FCDS Radiation Therapy 
 
Code Description 
0 No radiation 
1 Beam radiation 
2 Radioactive implant 
3 Radioisotopes 
4 Combinations of 1 with 2 and/or 3 
5 Radiation, NOS (Not Otherwise Specified) 
6 Patient or patient’s guardian refused 
7 Radiation therapy recommended, unknown if administered 
8 Unknown if radiation therapy administered 
 
For the purpose of this study radiation will be broken down into two categories: 
No radiation (consisting of code 0) and any type of radiation received or planned (Codes 
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1, 2, 3, 4, 5, and 8).  Subjects whose radiation treatment status is unknown (codes 7 and 
9) will not be included in the analysis (Bradley 2002). 
Predictor Variable of Interest 
Race.  Race will be defined as a dichotomous, categorical variable with the case's 
race being defined as White or Black. Other racial/ethnic groups such as Asian, Native 
American and Hispanic are excluded from this study because they vary widely in their 
cancer outcomes, and combining such disparate groups into the study can lead to biased 
results (Bradley 2001).  A broad-based population outcomes study by Studnicki, et al., set 
in one county in Florida concluded that there are research constraints in the limited 
number of ethnically identified indicators and, especially for Hispanics, problems in the 
accuracy and consistency of the assignment to racial categories and subsequent reporting 
(Studnicki 2004).  Also, subjects who are self-identified as "Multiracial" in the FCDS 
data set will be excluded from the study. 
Covariates 
Age.  Iezzonie writes that age is "simple straight forward…[has] good face 
validity…is almost always available, and [we] expect age to be in the model" (2003).  It 
is standard in all risk adjustment modeling.  Age is of particular interest in the study of 
breast cancer because a woman's risk of developing this disease increases during her 
lifetime.  Some 80% of breast cancers occur in women older than 50.  By age 70, a 
woman's chances of developing breast cancer are 1 in 24 (Elk 2003).  In the study of 
breast cancer disparities age plays a significant role because black women younger than 
40 have slightly higher rates of breast cancer diagnosis than white women in the same 
age group (Elk 2003). 
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Age by itself is a continuous variable and in the descriptive analysis of the data 
will at first be evaluated as such using univariate analysis; however, for the purpose of 
responding to the hypotheses, Age will become a categorical variable, stratified into four 
age groups depending on age at time of diagnosis.  Subjects with missing or incomplete 
age will be categorized as “Unknown” and excluded from the study.  Because of findings 
by Farrow and Ballard-Barbash that stress age as an indicator for declining use of radio 
therapy post-breast conserving surgery, age as a variable will be evaluated categorically 
to best present the difference across strata (Farrow 1992, Ballard-Barbash 1996). The 
subjects will be categorized into the following groups as listed in Table 3. 
 
Table 3 
 
Age Categories and Descriptions 
Code Description 
1 Young (<50) (Reference Group) 
2 Middle Age (50-64) 
3 Old (65-79) 
4 Very Old (80+) 
 
 
Although other studies have divided age groups by ten-year intervals or created an 
open-ended 65+ age group, this study will use the aforementioned four categories for age.  
Using ten-year age groups produces a large number of categories so that the observations 
are stretched over too many categories and patterns may not be easily discerned in the 
resulting cross tabulation. For the later, 65+ age group (used in studies that relate pre-, 
during and post-menopausal status to breast cancer), Rothman says that a category with 
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"no upper limit allows for a considerable range of variability within which the desired 
homogeneity of exposure or risk may not be achieved" (206).  Thus, the creation of the 
80+ group will bring to light the experience of the increasing number of "oldest old."  
One study shows that although elderly cancer patients often receive less aggressive 
treatment, they spend more time discussing limitations of treatments with their physicians  
(Iezzoni 2003, Rose 2000). 
Payer.  Primary payer of health care for breast cancer treatment is considered an 
imported independent variable by many researchers.  In the case of BCS versus 
Mastectomy, previous research has contraindications of what are the effects of Medicaid 
insurance.  Studies by Bradley and Morrow show Medicaid as a great equalizer of 
surgical option used, where as Luther found that women in Florida were twice as likely to 
receive mastectomies if Medicaid was the primary insurance payer.  (Bradley 2002, 
Morrow 2001, Luther 2001). 
Primary payer is a categorical variable. The FCDS database includes a multitude 
of categories which will be divided into five categories as shown in Table 4. 
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Table 4 
Primary Payer Categories and Descriptions 
Code Description 
1 Private insurance and Managed Care:  (Reference group) 
  Managed care provider, NOS 
Health Maintenance Organization (HMO) 
Preferred Provider Organization (PPO) 
Insured, Type Unknown 
Unknown insurance 
Champus 
Military 
2 Medicare (Federally funded insurance types) 
  Medicare 
Veterans Administration 
Indian Health Services 
Public Health Services 
3 Medicaid 
  State funded, NOS 
Medicaid 
Welfare 
4 Uninsured:  Not Insured, NOS 
  Not insured, charity write-off 
Not insured, self-pay 
5 Unknown 
 
 
Champus and Military insurance were categorized in the Private insurance group 
because previous studies have found that women in these groups share numerous 
demographic characteristics as privately insured women.  These characteristics include 
age, race, and stage at diagnosis (Richardson 2004). 
Rurality.  The FCDS includes the case's county of residence and zip code of 
residence at the time of diagnosis. Luther and Studnicki found that residing in a rural 
rather than an urban area was significantly associated with the use of mastectomy over 
BCS  (Luther  2001). As shown in the review of the literature section, studies by 
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Nattinger and Parviz have evaluated the effect of rurality in terms of distance to a 
treatment center for radiation therapy (Nattinger 2001, Parviz 2003).  The rurality 
measure to be employed in this project is adapted from the United States Department of 
Agriculture's (USDA) Rural-Urban Continuum Codes which were produced by the 
Economic Research Service. The application of a continuum rather than a dichotomous 
break down of Urban versus Rural will enable isomorphic comparisons across categories. 
Rural-Urban Continuum Codes form a classification scheme that distinguishes 
metropolitan (metro) counties by the population size of their metro area, and Non 
Metropolitan (Non Metro) counties by degree of urbanization and adjacency to a metro 
area or areas. The metro and Non Metro categories have been subdivided into three metro 
and six Non Metro groupings, resulting in a nine-part county codification. The codes 
allow researchers working with county data to break such data into finer residential 
groups beyond a simple metro-Non Metro dichotomy, particularly for the analysis of 
trends in Non Metro areas that may be related to degree of rurality and metro proximity. 
All U.S. counties and county equivalents are grouped according to their official 
metro-Non Metro status announced by the Office of Management and Budget (OMB) in 
June 2003, when the population and worker commuting criteria used to identify metro 
counties were applied to results of the 2000 Census. Metro counties are distinguished by 
population size of the Metropolitan Statistical Area of which they are part. Non Metro 
counties are classified according to the aggregate size of their urban population. Within 
the three urban size categories, Non Metro counties are further identified by whether or 
not they have some functional adjacency to a metro area or areas. A Non Metro county is 
defined as adjacent if it physically adjoins one or more metro areas, and has at least 2 
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percent of its employed labor force commuting to central metro counties. Non Metro 
counties that do not meet these criteria are classed as nonadjacent  (USDA  2003). 
All nine of the categories of rural-urban do not apply to the state of Florida. Some 
adaptation of the Rural-Urban Continuum codes is necessary in order to maintain the 
statistical power of this study. One area that was changed was a collapsing of the last two 
categories that apply to Florida because of small sample size within the last stratum 
(Levels 6 and 8). The original USDA codes are listed in Table 5.  
 
Table 5 
USDA Rural-Urban Continuum Codes 
Code Description 
 Metro counties: 
1 Counties in metro areas of 1 million population or more. 
2 Counties in metro areas of 250,000 to 1 million population. 
3 Counties in metro areas of fewer than 250,000 population. 
 Non Metro counties: 
4 Urban population of 20,000 or more, adjacent to a metro area.  
5 Urban population of 20,000 or more, not adjacent to a metro area. 
6 Urban population of 2,500 to 19,999, adjacent to a metro area. 
7 Urban population of 2,500 to 19,999, not adjacent to a metro area. 
8 Completely rural or less than 2,500 urban population, adjacent to a metro 
area. 
9 Completely rural or less than 2,500 urban population, not adjacent to a metro 
area. 
 (USDA 2003) 
 
 
 
It is noteworthy that none of the "Not adjacent to metro area" codes apply to 
Florida, which may be an artifact of the state's geographic layout as a long narrow 
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peninsula and panhandle. The USDA codes as they apply to Florida's sixty-seven 
counties are listed in Table 6. 
 
Table 6 
Florida Counties by USDA Rural-Urban Continuum Codes 
Code Counties 
1 Baker, Broward, Clay, Duval, Hernando, Hillsborough, Lake, Miami-
Dade, Nassau, Orange, Osceola, Palm Beach, Pasco, Pinellas, St. Johns, 
Seminole  (Reference Group) 
2 Brevard, Collier, Escambia, Gadsden, Jefferson, Lee, Leon, Manatee, 
Marion, Martin, Polk, St. Lucie, Santa Rosa, Sarasota, Volusia, Wakulla 
3 Alachua, Bay, Charlotte, Gilchrist, Indian River, Okaloosa 
4 Citrus, Flagler, Hendry, Highlands, Monroe, Okeechobe, Putman, Sumter
6 Bradford, Calhoun, Columbia, DeSoto, Dixie, Franklin, Glades, Gulf, 
Hamilton, Hardee, Holmes, Jackson, Madison, Suwannee, Taylor, Union, 
Walton, Washington 
8 Lafayette, Liberty 
88 Out of State, Out of Country 
90 Unknown 
 
 
In order to create a more parsimonious measure of rurality and to increase the 
statistical power of the categories during analysis, it becomes necessary to further group 
the counties in Florida into the following categories described in Table 7. 
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Table 7 
Urban-Rural Categories and Descriptions Used in Analysis 
Category Description 
Metro Includes USDA Code 1. Counties in metro areas of 1 million population 
or more. 
Small Metro Includes USDA Codes 2 and 3. Counties in metro areas of fewer than 1 
million population. 
Non Metro Includes USDA Codes 4,6 and 8. Urban population of 20,000 or less 
adjacent to a metro area or completely rural adjacent to a metro area. 
Unknown FCDS Codes 88 and 90. Out of State, Out of Country and Unknown. 
 
 
Cases that fall into the Unknown category are excluded from further study 
because they fail to contribute to the overall picture of disparities in breast cancer surgical 
treatment and radiation therapy use in the state of Florida.  
Marital status.  Although much has been written on the impact of marital status 
on the increased use of breast cancer screening and stage of diagnosis (Miller 2002, 
Mandelblatt 1991, Suarez 1994, Roetzheim 1999), little has been written on the effects of 
marital status and the appropriate use of breast conserving surgery and radiation therapy.  
Marital status is used to represent a degree of social support available to the case. This 
project will evaluate the impact of marital status on the dependent variables.  Information 
in the FCDS provides for four possible categories as described in Table 8. 
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Table 8 
Marital Status Codes and Descriptions 
Code Description 
1 Married (Reference group) 
2 Never Married (Single) 
3 Other (Divorced, Separated, Widowed) 
4 Unknown 
 
 
Nachmias and Nachmias point out the possible lack of exhaustiveness in this 
enumeration of categories (Frankfurt-Nachmias  1996).  Respondents who are "living 
together" with an opposite sex or same sex partner or an elderly parent who lives with an 
adult child do not fit accurately into this scheme, yet might exhibit the same level of 
social support as subjects in the "Married" category.  
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Results 
Overview 
This chapter presents the results of the data analysis conducted for the study.  The 
chapter begins with a detailed explanation of the reduction of the initial data set including 
all records from FCDS for 2001 to the final data set used in the analysis.  As previously 
outlined, the next set of information encompasses the entire eligible population for 
Hypothesis One, which looks for a Black/White racial disparity in the use of Breast 
Conserving Surgery.  First, the univariate analysis presents descriptive statistics for the 
entire population.  Next, the bivariate analysis shows the relationship between the 
predictor variable of interest, Race, when evaluated according to each of the covariates.  
Next information is presented about the iterative processes for determining which of the 
covariates are most useful in the explanation of the dependent variable, BCS use, and the 
unadjusted and adjusted odds ratios (OR’s) are given as well as the 95% Confidence 
Intervals. After the results from Hypothesis One are fully outlined, then the process is 
repeated for Hypothesis Two, which focuses on the smaller population of BCS recipients 
and the receipt of Radiation Therapy. 
Data Reduction 
Based upon the criteria previously detailed in the Methods chapter, a considerable 
amount of data reduction was necessary in order to produce the final data set for analysis.  
The process is illustrated in Figure 2.  
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Each record in the FCDS dataset represents one tumor.  The data reduction 
process began by identifying tumors exclusively identified as being breast cancer (C50.0-
C50.9), which consisted of 20,969 tumors (Box A). Next, 172 tumor records were 
removed because of a gender identity other than female, leaving 20,797 (Box B). There 
were no tumors occurring in the same person that were coded as female in one record and 
some other gender in another record. 
With respect to ethnicity, there were 2,393 tumors identified as belonging to 
Hispanics, and they were removed (Box C), leaving 18,404.  Next, there were 283 tumors 
identified as belonging to individuals with a race other than Black or White, and they 
were removed, leaving 18,121 (Box D).  Seven (7) tumors were removed for discrepant 
race entries (i.e., tumors on the same person reported the person as Black in one record, 
and White in another), leaving 18,114 (Box E). 
To limit tumors to those with local state breast cancer, 9,238 were removed, 
leaving 8,876 (Box F).  Those coded as not falling into either the BCS or Mastectomy 
group were removed (n=217), leaving 8,659 (Box G).  In the case of multiple tumor 
surgeries for the same individual coded for BCS and Mastectomy, the BCS records were 
removed (n=117), as Mastectomy would be the most definitive surgical option.  This 
exclusion left 8,542 tumors (Box H).   
With respect to Radiation Therapy (RT), when there were multiple tumors on the 
same patient, only the most recent record would theoretically report RT because as the 
individual moved through the continuum of cancer care, Radiation Therapy would be 
among the last steps registered in the FCDS.  In this case, tumors reporting treatment 
with RT were kept, and the others removed (n=510), leaving 8,032 (Box J). 
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In the case multiple tumor records for the same individual reporting a different 
age for the individual, the row with the earliest age of diagnosis was retained (n = 8,017, 
Box K), and the rest removed (n=15). 
To conduct the planned analysis, it was necessary to reduce the data set to one 
tumor per person.  To accomplish this, tumors on individuals who still had more than one 
tumor represented in the data set were evaluated for missing data.  Those with the most 
missing data were removed (n=53), and 7,964 records were retained (Box L).  As the 
planned analysis involved an evaluation of the impact of insurance type, those with 
multiple tumors reporting inconsistent insurance were removed (n=81), leaving 7,883 
(Box M).  Finally, for those individuals still representing multiple tumors in the data set, 
tumors were randomly removed (n=487) so that each individual contributed 1 tumor to 
the data set (n=7,396, Box N). 
Because the analysis is limited to individuals in Florida, individuals coded as 
outside the state were removed (n=217), leaving a final data set of 7,179 individuals 
representing one tumor each (Box P). 
 
Figure 3.  Data Reduction Strategy. 
Male = 150
Other (Intersexed) = 1
Transsexual = 2
Unknown/not stated = 19
Mexican = 43
Puerto Rican = 89
Cuban = 396
South or Central American = 221
Other  Spanish/Hispanic Origin = 33
NOS, Spanish/Hispanic Origin = 1,264
Spanish surname only = 81
Unknown whether Spanish or not = 266
American Indian = 12
Chinese = 11
Japanese = 10
Filipino = 17
Hawaiian = 1
Korean = 3
Asian Indian/Pakistani = 24
Vietnamese = 11
Thai = 2
Asian non-specified = 30
Pacific Islander non-specified = 6
Other = 54
Unknown = 102
Box B 
Tumors on 
women only 
n=20,797 
Tumors not on 
women 
n=172 
Box C 
Tumors on non-
Hispanics only 
n=18,404 
Tumors not on 
Hispanics 
n=2,393 
Box D 
Tumors on Blacks 
or Whites 
n=18,121 
Tumors not on 
Blacks or Whites
n=283 
Box E 
Tumors on cases 
with consistent 
race reporting 
n=18,114 
Tumors on cases 
with discrepant 
race reporting 
n=7 
Box F 
Tumors in Local 
stage 
n=8,876 
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Tumors not in 
Local stage 
n=9,238 
Box A 
BCA tumors 
n=20,969 
In situ = 3,022
Regional/direct extension = 195
Regional/nodes only = 3,405
Regional/direct extension and nodes =
357
Regional, non-specified = 45
Distant/systemic disease = 631
Unknown = 1,583
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Figure 3.  (Continued). 
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Hypothesis One, Breast Conserving Surgery Use 
Descriptive Statistics, Univariate.  Hypothesis One asked if Black women in 
Florida in 2001 were statistically significantly less likely than White women to receive 
breast conserving surgery rather than a mastectomy for treatment of localized breast 
cancer.  Table 9 summarizes the univariate descriptive information for the study 
population who had Local stage breast cancer and were eligible for the study based on the 
previously discussed criteria. The total number of cases included in this study was 7,179. 
Of those cases, 66 percent (4,763) underwent breast conserving surgery and the 
remaining 44 percent (2,416) had mastectomies.  The same table shows the exact 
numbers and proportions of women in the total population for each covariate further 
stratified by the outcome variable. The racial distribution of the study shows that Black 
cases constituted 6 percent of the total population (460 Black v. 6719 White).  The 
proportion of participants in each age category continues to increase with the exception 
of the Very Old category.  The mean age for cases was 64.95 with a standard deviation of 
13.54 years. 
For the variable Marital Status, 56 percent (n = 4054) or the majority of the 
population in this data set fall into the Married category with the next populous category, 
Other, being comprised of 31 percent (n = 2243) of the population.  Insurance Type had 1 
percent of the population on Medicaid, 3 percent Uninsured, 48 percent on Medicare, 45 
percent had Private insurance and 3 percent were Unknown.  In the initial version of the 
USDA Rural-Urban Continuum 4,164 (58%) of the population lived in a Metro area 
larger than 1 million people; 2,170 (30%) lived in a Metro area with 250K-1 million 
people; 416 (6 %) lived in a Metro area with less than 250K; 126 (2 %) lived in a Non 
Metro area with greater than or equal to 20K; and 15 cases (0 %) lived in Non Metro 
areas with less than 2.5K people.  In order to make meaningful comparisons for 
populations living in all areas, the description of the final Rural-Urban codes used in 
analysis were as follows:  4,164 (58%) in Metro areas; 2,586 (36%) in Small Metro areas; 
and 423 (6%) in Non Metro. 
Table 9 also looks at the Outcome variable, Surgical Treatment for the entire 
population. Sixty-six percent of the population had Breast Conserving Surgery. For the 
Age categories, Middle Age (55-64) and Old (65-79) higher percentages of cases 
undergoing Breast Conserving Surgery and Mastectomy than in either of the two other 
Age categories.  
 
Table 9 
Descriptive Statistics for Local Stage Breast Cancer Population. 
    Total BCS Mastectomy 
    N Percentage N Percentage N Percentage 
Total N   7179 100% 4763 100% 2416 100% 
Surgery Type BCS 4763 66% XX XX XX XX 
  Mastectomy 2416 34% XX XX XX XX 
Race White 6719 94% 4477 94% 2242 93% 
  Black 460 6% 286 6% 174 7% 
Age Groups Young >50 1132 16% 715 15% 417 17% 
  Middle Age 50-64 2143 30% 1443 30% 700 29% 
  Old 65-80 2857 40% 1955 41% 902 37% 
  Very Old 80+ 1047 15% 650 14% 397 16% 
                  Mean, SD:  Young:  43.4, 13.5  Middle: 57.3, 4.2  Old: 72.1, 4.23  Very Old: 84.2, 3.78 
Marital Groups Married 4054 56% 2748 58% 1306 54% 
  Single 672 9% 413 9% 259 11% 
  Other 2243 31% 1455 31% 788 33% 
  Unknown 210 3% 147 3% 63 3% 
 
37 
Table 9 (Continued) 
  Total BCS Mastectomy 
  N Percentage N N Percentage N 
Insurance Type Medicaid 99 1% 51 1% 48 2% 
  Medicare 3478 48% 2314 49% 1164 48% 
  Private 3235 45% 2192 46% 1043 43% 
  Uninsured 182 3% 76 2% 106 4% 
  Unknown 185 3% 130 3% 55 2% 
Rural/USDA-
all Metro >= 1 mill 4164 58% 2784 58% 1380 57% 
  
Metro 250k-1 
mill 2170 30% 1480 31% 690 29% 
  Metro <250k 416 6% 258 5% 158 7% 
  
Non Metro 
>=20k 282 4% 164 3% 118 5% 
  
Non Metro 2.5-
20k 126 2% 65 1% 61 3% 
  Non Metro <2.5k 15 0% 9 0% 6 0% 
  
Unknown/Out of 
State 6 0% 3 0% 3 0% 
Rural/USDA-
Collapsed Metro >= 1 mill 4164 58% 2784 58% 1380 57% 
  Small Metro 2586 36% 1738 36% 848 35% 
  Non Metro 423 6% 238 5% 185 8% 
  
Unknown/Out of 
state 6 0% 3 0% 3 0% 
 
 
Descriptive Statistics, Bivariate.  Table 10 provides a more in-depth overview of 
the local stage breast cancer population in the study by detailing the number of cases and 
the appropriate percentages when evaluating the relationship between the predictor 
variable of interest, Race, according to each of the covariates. White cases constituted 
6719 of the total 7,179 cases used in the study, or 93.59 percent. There were 460 Black 
cases or 6.4 percent.  In the Age categories, White cases fell predominantly into the 
Middle Age (50-64 years) and Old Age (65-80 years old) groups with 1,976 (29%) in 
Middle Age and 2,735 (41%) in Old Age.  The highest percentage categories for Black 
cases were Young (134 cases, 29%) and Middle Age (167 cases, 36%).  Table 11 
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presents a more detailed look at differences within Age categories according to Race.  
For White cases the average age at diagnosis was 65.38 years with a standard deviation of 
13.4 years.  Black cases had a range of 27-96 years of age with a mean of 58.64 years of 
age at diagnosis.  The Black standard deviation was 14.06 years.  Overall, the Black 
category had younger mean ages within age categories and larger intra-category standard 
deviations than the White category.  Figure 3 graphically illustrates the differences in age 
distribution between Black and White categories. 
Returning to Table 10, under Marital Status, the majority, 58%, of White cases 
fell into the Married category (n = 3,877). Black cases had a more level distribution 
among the three categories: Married, 38%; Single, 24%; and Other 33%.  Health 
Insurance Type had White cases broken down as follows: Medicare, 50%; Private, 45%, 
Uninsured, 2%; and Medicaid, 1%. Black cases fell into the following categories for 
Insurance Type:  Private, 53%, Medicare, 33%, Uninsured, 6% and Medicaid, 5%. 
Rurality for White cases was divided as follows: 57% in Metro areas, 37% in Small 
Metro areas, and 6% in Non-Metro areas. Black cases fell into the following categories: 
69% in Metro areas, 26% in Small Metro areas, and 5% in Non-Metro areas. Figure 3 
visually presents the variation between Black and White cases in a series of histograms 
for each of the covariates. 
Table 10 also describes the crude relationship between the variable of interest, 
Race, and the outcome variable, Surgery Type, with 67% of White cases and 62% of 
Black cases undergoing Breast Conserving Surgery.  Percentage-wise, Black women 
were less likely to receive Breast Conserving Surgery, but the difference was not quite 
statistically significant (Crude OR=.823, CI=.677-1.00). 
Table 10 
Bivariate Descriptive Statistics, Categorical Covariates by Race 
  White Black 
  N % N % 
Total N  6719 100 460 100 
Age Groups Young >50 998 15 134 29 
 Middle Age 50-64 1976 29 167 36 
 Old 65-79 2735 41 122 27 
 Very Old 80+ 1010 15 37 8 
Marital Groups Married 3877 58 177 38 
 Single 563 8 109 24 
 Other 2091 31 152 33 
 Unknown 188 3 22 5 
Surgery Type BCS 4477 67 286 62 
 Mastectomy 2242 33 174 38 
Insurance Type Medicaid 77 1 22 5 
 Medicare 3326 50 152 33 
 Private 2990 45 245 53 
 Uninsured 155 2 27 6 
 Unknown 171 3 14 3 
Rural/USDA-All Metro >= 1 mill 3845 57 319 69 
 Metro 250k-1 mill 2073 31 97 21 
 Metro <250k 395 6 21 5 
 Non Metro >=20k 275 4 7 2 
 Non Metro 2.5-20k 111 2 15 3 
 Non Metro <2.5k 15 0 0 0 
 Unknown/Out of State 5 0 1 0 
Rural/USDA 
Collapsed Metro >= 1 mill 3845 57 319 69 
 Small Metro 2468 37 118 26 
 Non Metro 401 6 22 5 
 Unknown/Out of State 5 0 1 0 
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Table 11 
Mean, SD, and Range of Age by Race. 
 White Black 
 N Mean SD Range N Mean SD Range 
Total N 6719 65.38 13.40 21-100 460 58.64 14.06 27-96 
Young >50 998 43.54 4.63 21-49 134 42.37 5.16 27-49 
Middle 50-64 1976 57.40 4.19 50-64 167 56.60 4.24 50-64 
Old 65-79 2735 72.16 4.23 65-79 122 71.32 4.23 65-79 
Very Old 80+ 1010 84.24 3.77 80-100 37 85.00 3.79 81-96 
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Figure 4.  Histograms of Bivariate Analysis of BCS by Race and Category 
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Figure 4. (Continued) 
 
Modeling.  The next items presented are the iterative processes for determining 
which of the covariates are useful to the explanation of the Outcome Variable, BCS use 
in its relation to Race. Multiple combinations of covariates and interaction terms were 
developed. The most relevant of the models that explain the impact of Race on BCS are 
illustrated in Appendix A.  Also, the role of the other covariates in terms of disentangling 
the impact of Race on BCS is illustrated.  The table clearly shows which of the covariates 
were statistically significant for each model as well as the Odds Ratio and 95% 
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Confidence Interval in models where Black is a statistically significant covariate. The 
value of the -2 Log Likelihood function and degrees of freedom (df) are also given for 
each equation in order to make meaningful comparisons while attempting to disentangle 
the effects of Race on the outcome BCS.   Log Likelihood functions are frequently used 
to compare the support given to competing hypotheses by the data (Rothman  1998, 
Goodman  1988).  Then Appendix B displays the comparison of models based on 
percentage change in Black covariate, the difference in Log Likelihood function, degrees 
of freedom and the chi-square p-value.  
Table 12 contains the parameter estimates, p-values, odds ratios and 95% 
confidence intervals for the crude model. Table 13 contains the same values for the full 
model. Table 14 presents the full model with all possible interaction terms including the 
predictor variable of interest, Race. The crude odds ratio for Black is 0.8230 and the term 
is barely statistically significant with a 95% Confidence Interval of 0.6670-1.000. The 
full model pushes Black into not being significant. In Table 13, the statistically 
significant terms include Single, Medicaid, Uninsured and Non-Metro. Other Married 
and Small Metro border on statistical significance with  95% confidence interval ranges 
of 0.802-1.008 and 0.889-1.099 respectively.   In Table 14 none of the possible 
interaction terms between the covariates and the predictor variable of interest prove to be 
statistically significant.  
Appendix B, Comparison of Models for Breast Conserving Surgery, illustrates the 
variation between the models that include various elements of Race, Age, Insurance 
Type, Marital Status and Rurality.  By calculating the -2 Log Likelihood differences and 
degrees of freedom and running a chi-square distribution, improvements in subsequent 
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logistic models can be determined.  The extreme Chi-square p-values resulting from 
comparisons of the A-series of models show that including other covariates proves useful 
in explaining the relationship between Race and Surgery Type.   
 
Table 12  
Crude Model for Surgical Treatment 
  
Parameter 
Estimate OR P-value 95% CI 
Crude 
Model Black -0.1947 0.8230 0.0506 0.6770 - 1.000 
 
 
Table 13 
Full Model for Surgical Treatment 
  
Parameter 
Estimate OR P-value 95% CI 
Full Model Black -0.1067 0.8990 0.2989 0.735 - 1.099 
 Young (<50) reference reference reference reference 
 Middle (50-64) 0.1618 1.1760 0.0389 1.008 - 1.371 
 Old (65-79) 0.2026 1.2250 0.0412 1.008 - 1.488 
 Very Old (80+) -0.0607 0.9410 0.5992 0.751 - 1.180 
 Married reference reference reference reference 
 Single -0.2142 0.8070 0.0155 0.679 - 0.960 
 Other -0.1059 0.9000 0.0689 0.802 - 1.008 
 Private reference reference reference reference 
 Medicare -0.0654 0.9370 0.4151 0.800 - 1.096 
 Medicaid -0.5406 0.5820 0.0092 0.388 - 0.875 
 Uninsured -1.0412 0.3530 <0.0001 0.260 - 0.479 
 Metro (>=1 million) reference reference reference reference 
 Metro (<1 million) -0.0117 0.9880 0.8288 0.889 - 1.099 
 Non-metro -0.4507 0.6370 <0.0001 0.519 - 0.783 
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Table 14 
Full Model with Interaction Terms for Surgical Treatment 
  
Parameter 
Estimate OR P-value 95% CI 
Interaction 
Model Black -0.1152 xx 0.6274 xx 
 Young (<50) reference reference reference reference 
 Middle (50-64) 0.1610 xx 0.0521 xx 
 Old (65-79) 0.1925 xx 0.0644 xx 
 Very Old (80+) -0.0557 xx 0.6436 xx 
 Married reference reference reference reference 
 Single -0.2297 xx 0.0156 xx 
 Other -0.1028 xx 0.0877 xx 
 Private reference reference reference reference 
 Medicare -0.0574 xx 0.4927 xx 
 Medicaid -0.6056 xx 0.0096 xx 
 Uninsured -1.1564 xx <0.0001 xx 
 Metro (>=1 million) reference reference reference reference 
 Metro (<1 million) -0.0058 xx 0.9177 xx 
 Non-metro -0.4211 xx 0.0001 xx 
 Young (<50) * Black reference reference reference reference 
 
Middle (50-64) * 
Black 0.0103 xx 0.9683 xx 
 Old (65-79) * Black 0.1336 xx 0.7092 xx 
 
Very Old (80+) * 
Black -0.2783 xx 0.5423 xx 
 Married * Black reference reference reference reference 
 Single * Black 0.1186 xx 0.6586 xx 
 Other * Black 0.0314 xx 0.8984 xx 
 Private * Black reference reference reference reference 
 Medicare * Black -0.1603 xx 0.5944 xx 
 Medicaid * Black 0.3111 xx 0.5492 xx 
 Uninsured * Black 0.7264 xx 0.1024 xx 
 
Metro (>=1 million) 
* Black reference reference reference reference 
 
Metro (<1 million) * 
Black -0.0784 xx 0.7354 xx 
 Non-metro * Black -0.4498 xx 0.3405 xx 
 
 
Tables 15 and 16 show the parameters of the best equations that explain the 
relationship between the covariates and the outcome are models C8 and C9. Both models 
include the covariates for Middle Age (50-64), Old Age (65-79), Very Old Age (80+), 
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Medicaid, Single, Other Married and Non-Metro.  However, only model C8 contains the 
variable of interest, Black.   
In order to better explain the relationship between the covariates and the outcome, 
Breast Conserving Surgery, all covariates were included in an iterative process of testing 
for interaction terms.  None of the attempts proved to be statistically significant.  The 
results of the modeling process can be seen in Appendix C.   
 
Table 15 
Candidate for Best BCS Explanatory Model with Black, C8 
Parameter 
Parameter 
Estimate SE OR 95% LL 95% UL P value 
Intercept 0.6574 0.0664 XX XX XX  <.0001 
BLACK -0.1326 0.1019 0.876 0.717 1.069 0.1931 
NON METRO -0.4600 0.1023 0.631 0.517 0.771  <.0001 
MIDAGE 0.1681 0.0776 1.183 1.016 1.377 0.0303 
OLDAGE 0.2087 0.0760 1.232 1.062 1.430 0.0060 
VERYOLD -0.0543 0.0936 0.947 0.788 1.138 0.5619 
MCAID -0.4690 0.2069 0.626 0.417 0.938 0.0234 
SINGLE -0.2262 0.0878 0.798 0.671 0.947 0.0100 
OTHMAR -0.1138 0.0580 0.892 0.796 1.000 0.0498 
 
 
Table 16 
Candidate for BCS Best Explanatory Model without Black, C9 
Parameter 
Parameter 
Estimate SE OR 95% LL 95% UL P value 
Intercept 0.6451 0.0657 XX XX XX  <.0001 
NON METRO -0.4580 0.1022 0.6325 0.5561 0.7195  <.0001 
MIDAGE 0.1726 0.0775 1.1884 1.0209 1.3833 0.0259 
OLDAGE 0.2176 0.0756 1.2431 1.0719 1.4416 0.0040 
VERYOLD -0.0432 0.0931 0.9579 0.7979 1.1494 0.6429 
MCAID -0.4846 0.2065 0.6159 0.4109 0.9232 0.0189 
SINGLE -0.2396 0.0872 0.7869 0.6633 0.9336 0.0060 
OTHMAR -0.1186 0.0579 0.8882 0.7929 0.9949 0.0406 
Hypothesis Two, Radiation Therapy Use 
Data Reduction.  Hypothesis 2 asks if Black women in Florida are statistically 
significantly less likely than White women to receive radiation therapy after breast 
conserving surgery.  Thus, a subset of cases from the larger data set used to answer the 
first hypothesis is needed in order to properly assess the relationship between Race and 
Radiation Therapy use.  Figure 4 details the additional data reduction steps used to 
answer Hypothesis Two.  The initial size of the sample is 4,763 cases that had breast 
conserving surgery.  Of these BCS cases, 2,066 had radiation therapy; 2,678 did not have 
radiation therapy; and 19 cases were unknown for radiation therapy. 
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Total Population 
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Radiation Therapy  
Yes 
N = 2,066 
Figure 5.  Data Reduction for Radiation Therapy Analysis 
 
Descriptive Statistics, Univariate.  Table 17 summarizes the univariate descriptive 
information for the study population who had breast conserving surgery and were 
otherwise eligible for inclusion in the study based on the previously discussed criteria. 
The total number of cases included in this portion of the study was 4,763.  All of these 
cases underwent breast conserving surgery for treatment of localized breast cancer.  Of 
those cases, 43 percent (2,066) had radiation therapy, 56 percent  (2,678) reported no 
radiation therapy, and 3 percent (19) were unknown for radiation therapy status.  Cases 
reporting unknown status will be excluded from further portions of this study. The same 
table shows the exact numbers and proportions of women in the total population for each 
covariate further stratified by the outcome variable. The racial distribution shows that 
Black cases constituted 6 percent of the BCS population (286 Black v. 4,477 White).  For 
Age groups, each age category continues to increase with the exception of the Very Old 
category.  Table 17 also shows the mean age 64.98 and standard deviation, 13.24 years, 
for the population included in this analysis. The age range for the study was 21- 100 
years.   
 
Table 17 
Descriptive Statistics of Breast Conserving Surgery Population 
  Total 
Radiation Therapy-
Yes 
No Radiation 
Therapy 
  N Percentage N Percentage N Percentage 
Total N  4763 100% 2066 100% 2678 100% 
Radiation 
Therapy Yes 2066 43% XX XX XX XX 
 No 2678 56% XX XX XX XX 
 Unknown 19 0% XX XX XX XX 
Race White 4477 94% 1948 94% 2512 94% 
 Black 286 6% 118 6% 166 6% 
Age Groups Young >50 715 15% 262 13% 447 17% 
 Middle Age 50-64 1443 30% 645 31% 794 30% 
 Old 65-79 1955 41% 936 45% 1012 38% 
 Very Old 80+ 650 14% 223 11% 425 16% 
                 Mean, SD:  Young: 43.4, 4.67  Middle: 57.4, 4.15  Old: 72.05, 4.23  Very Old: 84.18, 3.79 
Marital 
Groups Married 2748 58% 1242 60% 1496 56% 
 Single 413 9% 158 8% 251 9% 
 Other 1455 31% 603 29% 848 32% 
 Unknown 147 3% 63 3% 83 3% 
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Table 17. (Continued) 
  Total 
Radiation Therapy-
Yes 
No Radiation 
Therapy 
  N Percentage N Percentage N Percentage 
Insurance 
Type Medicaid 51 1% 21 1% 30 1% 
 Medicare 2314 49% 1032 50% 1275 48% 
 Private 2192 46% 930 45% 1250 47% 
 Uninsured 76 2% 26 1% 50 2% 
 Unknown 130 3% 57 3% 73 3% 
Rural/USDA-
all Metro >= 1 mill 2784 58% 1126 55% 1644 61% 
 Metro 250k-1 mill 1480 31% 741 36% 736 27% 
 Metro <250k 258 5% 115 6% 141 5% 
 Non Metro >=20k 164 3% 54 3% 110 4% 
 Non Metro 2.5-20k 65 1% 24 1% 41 2% 
 Non Metro <2.5k 9 0% 5 0% 4 0% 
 
Unknown/Out of 
State 3 0% 1 0% 2 0% 
Rural/USDA-
Collapsed Metro >= 1 mill 2784 58% 1126 55% 1644 61% 
 Small Metro 1738 36% 856 41% 877 33% 
 Non Metro 238 5% 83 4% 155 6% 
 
Unknown/Out of 
state 3 0% 1 0% 2 0% 
 
 
Table 17 also shows that for the variable Marital Status, 58 percent (n = 2,748), 
the overwhelming majority of the population in this data set fall into the Married category 
with the next populous category, Other, being comprised of 31 percent (n = 2243) of the 
population.  Insurance Type had 1 percent of the population on Medicaid, 2 percent 
Uninsured, 49 percent on Medicare, 46 percent had Private insurance and 3 percent were 
Unknown.  In the initial version of the USDA Rural-Urban Continuum 2,784 (58%) of 
the population lived in a Metro area larger than 1 million people; 1,480 (31%) lived in a 
Metro area with 250K-1 million people; 258 (5 %) lived in a Metro area with less than 
250K. For Non Metro populations, 164 (3%) lived in a Non Metro area with greater than 
or equal to 20K; 65 cases (1 %) lived in Non Metro areas with between 2.5-20,000; 9 
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cases of were in areas with less than 2,500 and 3 cases fell into the Unknown/Out of State 
category and were eliminated from further analysis.  The Collapsed Rural-Urban 
categorical breakdown used in analysis is as follows: 2,784 (58%) in Metro areas; 1,738 
(36%) in Small Metro areas; and 238 (5%) in Non Metro.  
In terms of Radiation Therapy Use, which is the Outcome variable for this 
hypothesis, Table 17 shows that of the 4,763 total cases, 2,066 (43%) had “Yes” for 
Radiation Therapy in the FCDS data set and 2,678 (56%) had “No” for Radiation 
Therapy.  There were 19 cases (0%) that were Unknown for Radiation Therapy Use and 
were excluded from further statistical analysis. 
Descriptive Statistics, Bivariate.  Table 18 provides a more in-depth overview of 
the breast conserving surgery population in the study by detailing the number of cases 
and the appropriate percentages when evaluating the relationship between the predictor 
variable of interest, Race, according to each of the covariates.  White cases constituted 
4,477 of the total 4,763 cases used in this portion of the study, or 94 percent.  There were 
286 Black cases or 6 percent. 
Table 18 
Descriptive Statistics, Categorical Covariates by Race for BCS 
  White Black 
  N Percentage N Percentage 
Total N  4477 100 286 100 
Age Groups Young >50 634 14 81 28 
 Middle Age 50-64 1336 30 107 37 
 Old 65-79 1875 42 80 28 
 Very Old 80+ 632 14 18 6 
MaritalGroups Married 2634 59 114 40 
 Single 347 8 66 23 
 Other 1363 30 92 32 
 Unknown 133 3 14 5 
RadiationTherapy Yes 1948 44 118 41 
 No 2512 56 166 58 
 Unknown 17 0 2 1 
InsuranceType Medicaid 39 1 12 4 
 Medicare 2222 50 92 32 
 Private 2036 45 156 55 
 Uninsured 61 1 15 5 
 Unknown 119 3 11 4 
Rural/USDA All Metro >= 1 mill 2580 58 204 71 
 Metro 250k-1 mill 1420 32 60 21 
 Metro <250k 245 5 13 5 
 Non Metro >=20k 160 4 4 1 
 Non Metro 2.5-20k 60 1 5 2 
 Non Metro <2.5k 9 0 0 0 
 
Unknown/ 
Out of State 3 0 0 0 
Rural/USDA 
Collapsed Metro >= 1 mill 2580 58 204 71 
 Small Metro 1665 37 73 26 
 Non Metro 229 5 9 3 
 
Unknown/ 
Out of state 3 0 0 0 
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In the Age categories, White cases fell predominantly into the Middle Age (50-64 
years) and Old Age (65-80 years old) groups with 1,336 (30%) in Middle Age and 1,875 
(42%) in Old Age.  The highest percentage category for Black cases was Middle Age 
(107 cases, 37%).  Young (>50) and Old Age (65-79) had equal parts of the Black cases 
with 81 and 80 cases respectively or an even 28% of the population for each category.  
There was no statistical significance in terms of placement in the Young age category 
between Black and White cases (OR: 2.39, 95% CI:  1.9808-3.0282).  Table 19 presents a 
more detailed look at differences in Race according to Age.   
 
Table 19 
Mean, SD, and Range of Age by Race for BCS Population 
 White Black 
 N Mean SD Range N Mean SD Range 
Total N 4477 65.38 13.13 21-100 286 58.79 13.46 28-96 
Young >50 634 43.52 4.67 21-49 81 42.79 4.61 28-49 
Middle Age  1336 57.49 4.14 50-64 107 57.01 4.34 50-64 
Old 65-79 1875 72.06 4.22 65-79 80 71.49 4.23 65-79 
Very Old 80+ 632 84.16 3.78 80-100 18 84.89 4.17 81-96 
 
 
For White cases the average age at diagnosis was 65.38 years with a standard 
deviation of 13.13 years.  The White range was 21-100 years.  Black cases had a range of 
28-96 years of age with a mean of 58.64 years of age at diagnosis. The Black standard 
deviation was 13.46 years.  Overall, the Black category had younger mean ages within 
age categories with the exception of the Very Old category where Black cases had a 
mean age of 84.89 versus 84.16 from White cases. 
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Returning to Table 18, under Marital Status, the majority, 59%, of White cases 
fell into the Married category (n = 2,634). 8% (n=347) into the Single category and 30% 
(n-1363) into the Other category with 3% (n=133) Unknown.  Black cases were 
distributed more equally across the Marital categories: Married, 40%; Single, 23%; and 
Other 32%.  Health Insurance Type had White cases broken down as follows: Medicare, 
50%; Private, 45%, Uninsured, 1%; and Medicaid, 1%. Black cases fell into the 
following categories for Insurance Type:  Private, 55; Medicare, 32%; Uninsured, 5%; 
and Medicaid, 4%. Rurality for White cases was divided as follows: 58% in Metro areas, 
37% in Small Metro areas, and 5% in Non Metro areas.  Black cases fell into the 
following categories: 71% in Metro areas, 26% in Small Metro areas, and 3% in Non 
Metro areas.  
Table 18 also shows the crude relationship between the variable of interest, Race, 
and the outcome variable, Radiation Therapy.  According to the information in the data 
set, for White cases 44% and for Black cases 41% received Radiation Therapy.  
Percentage-wise, Black women were less likely to receive Radiation Therapy following 
Breast Conserving Surgery, but the difference was not statistically significant (Crude 
OR= 0.917, CI=0.719-1.17). 
Modeling.  The next items presented are the iterative processes for determining 
which of the covariates are useful to the explanation of the Outcome Variable, Radiation 
Therapy (RT-Yes) use in its relation to Race. Numerous models were developed in order 
to accomplish this task using all combinations of covariates and interaction terms. The 
most relevant of the models that explain the impact of Race on receipt of radiation 
therapy (RT-Yes) are illustrated in Appendix D.  Also, the role of the other covariates in 
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terms of teasing out the impact of Race on RT-Yes is illustrated.  The table clearly shows 
which of the covariates were statistically significant for each model as well as the Odds 
Ratio and 95% Confidence Interval for equations that include Black.  The -2 Log 
Likelihood value and degrees of freedom (df) are also given for each equation in order to 
make meaningful comparisons between models.  Appendix E then displays the 
comparison of models based on percentage change in Black covariate, the difference in -2 
Log Likelihood function, degrees of freedom and the chi-square p-value.  
Tables 20, 21 and 22 present summaries of the crude and full models as well as 
the full model with all possible interaction terms relating Black to the other covariates.  In 
Table 20, the crude OR for Black is 0.917.  The relationship is not statistically 
significant, 95% CI:  0.719-1.170.  The full model given in Table 21 has the following 
significant covariates:  Middle Age (50-64), Old (65-79) and Non-Metro.  The two 
Marital Status terms Single and Other were outside the range of statistical significance 
with upper limits to the 95% Confidence Interval ranges of 1.03.  Table 22 is the full 
model with all possible covariates interacting with the predictor variable of interest, Race. 
Statistical significance in this model is based on the p-value for each possible covariate or 
interaction term. Significant covariates included Middle Age (50-64), Old (65-79).  Small 
Metro and Non-Metro was just out of range with a p-value of .0609.  The interaction term 
between Black and Medicaid proved to be statistically significant. 
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Table 20 
Crude Model for RT 
Crude Model Parameter Estimate OR P-value 95% CI 
Black -0.0866 0.9170 0.4856 0.7190 - 1.1700 
 
 
Table 21 
Full Model for RT 
Full Model Parameter Estimate OR P-value 95% CI 
Black 0.0116 1.0120 0.9278 0.788 - 1.299 
Young (<50) reference reference reference reference 
Middle (50-64) 0.3197 1.3770 0.0008 1.143 - 1.659 
Old (65-79) 0.4157 1.5150 0.0005 1.200 - 1.913 
Very Old (80+) -0.1156 0.8910 0.4236 0.617 - 1.182 
Married reference reference reference reference 
Single -0.1879 0.8290 0.0901 0.667 - 1.030 
Other -0.1002 0.9050 0.1443 0.791 - 1.035 
Private reference reference reference reference 
Medicare 0.0417 1.0430 0.6587 0.867 - 1.254 
Medicaid 0.0545 1.0560 0.8520 0.595 - 1.872 
Uninsured -0.2697 0.7640 0.2772 0.469 - 1.242 
Metro (>=1 million) reference reference reference reference 
Small Metro 0.3331 1.3950 <0.0001 1.235 - 1.576 
Non-metro -0.2845 0.7520 0.0466 0.569 - 0.996 
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Table 22 
Full Model with Interaction Terms for RT 
Interaction Model Parameter Estimate OR P-value 95% CI 
Black 0.0910 xx 0.7629 xx 
Young (<50) reference reference reference reference 
Middle (50-64) 0.3347 xx 0.0009 xx 
Old (65-79) 0.4288 xx 0.0006 xx 
Very Old (80+) -0.0890 xx 0.5528 xx 
Married reference reference reference reference 
Single -0.2239 xx 0.0609 xx 
Other -0.1051 xx 0.1375 xx 
Private reference reference reference reference 
Medicare 0.0518 xx 0.5971 xx 
Medicaid -0.2873 xx 0.4075 xx 
Uninsured -0.3875 xx 0.1707 xx 
Metro (>=1 million) reference reference reference reference 
Small Metro 0.3360 xx <0.0001 xx 
Non-metro -0.2730 xx 0.0613 xx 
Young (<50) * Black reference reference reference reference 
Middle (50-64) * Black -0.1624 xx 0.6181 xx 
Old (65-79) * Black -0.1809 xx 0.6824 xx 
Very Old (80+) * Black -1.0751 xx 0.1512 xx 
Married * Black reference reference reference reference 
Single * Black 0.2891 xx 0.3937 xx 
Other * Black 0.2322 xx 0.4438 xx 
Private * Black reference reference reference reference 
Medicare * Black -0.2590 xx 0.4946 xx 
Medicaid * Black 1.5022 xx 0.0452 xx 
Uninsured * Black 0.5283 xx 0.3905 xx 
Metro (>=1 million) * 
Black reference reference reference reference 
Small Metro * Black -0.0970 xx 0.7539 xx 
Non-metro * Black -0.3826 xx 0.6248 xx 
 
 
In order to better explain the relationship between the covariates and the outcome, 
receipt of Radiation Therapy, all covariates were included in an iterative process of 
testing for interaction terms.  The J-series of models in Appendix D show the significant 
covariates and the -2 Log Likelihood and degrees of freedom for each model.  The 
interaction of Black and Medicaid proved to be statistically significant.  The initial results 
of the comprehensive interactive modeling process can be seen in Appendix F. 
Proportion of BCS Participants Receiving Radiation Therapy by Race in Each Insurance 
Category
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Figure 6.  Histogram of Bivariate Analysis by Race and Payer for RT 
 
The interaction term between Black and Medicaid provides a better explanatory 
model and can be seen in Appendix E by the comparison between models C10 and J16. 
The same interaction results are clearly visible in Figure 6, Histogram of Bivariate 
Analysis by Race and Payer for RT.   The significance of the chi-square distribution p-
value demonstrates that the interaction term must be included.  Tables 23 and 24 show 
the parameters of the two best equations that explain the relationship between the 
covariates and the outcome are models J15 and J16. Both models include the covariates 
for Middle Age (50-64), Old Age (65-79), Very Old Age (80+), Medicaid, Single, Other 
Married, Metro, Small Metro, Non-Metro and the interaction term of Black*Medicaid.   
Due to the paucity of covariates for inclusion in the models as well as the importance of 
Marital Status in the literature, Model J16 is the best explanatory model for the 
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relationship between Race and receipt of Radiation Therapy.  Among the other models 
that are in the J-series of models and include interaction terms, when J18 and J19 are 
compared to model J16, there proves to be no significant difference when removing the 
two Marital Status covariates, Single and Other Married.  
 
Table 23 
Candidate for Best Explanatory Model, J15 
Parameter Parameter  Estimate  SE P value OR 95% LL 95% UL 
Intercept -0.6365 0.0837  <.0001 xx xx xx 
BLACK -0.0760 0.1293 0.5567 0.9268 0.8144 1.0547 
MIDAGE 0.3204 0.0947 0.0007 1.3780 1.1440 1.6590 
OLDAGE 0.4484 0.0911  <.0001 1.5660 1.3100 1.8720 
VERYOLD -0.1090 0.1147 0.3417 0.8970 0.7160 1.1230 
MCAID -0.3446 0.3455 0.3186 0.7085 0.5015 1.0009 
SMALL METRO 0.3379 0.0622  <.0001 1.4020 1.2410 1.5840 
NON-METRO -0.2818 0.1428 0.0485 0.7540 0.5700 0.9980 
BLACK*MCAID 1.5046 0.7159 0.0356 4.5024 2.2005 9.2119 
 
 
Table 24 
Candidate for Best Explanatory Model, J16 
Parameter Parameter Estimate SE P value OR 95% LL 95% UL 
Intercept -0.5908 0.0866 <.0001 xx xx xx 
BLACK -0.0451 0.1303 0.7295 0.9559 0.8391 1.0889 
MIDAGE 0.3157 0.0951 0.0009 1.3710 1.1380 1.6520 
OLDAGE 0.4472 0.0927 <.0001 1.5640 1.3040 1.8760 
VERYOLD -0.0845 0.1194 0.4789 0.9190 0.7270 1.1610 
MCAID -0.3043 0.3462 0.3793 0.7376 0.5218 1.0428 
SMALL METRO 0.3319 0.0623 <.0001 1.3940 1.2330 1.5740 
NON-METRO -0.2916 0.1430 0.0414 0.7470 0.5640 0.9890 
SINGLE -0.1889 0.1112 0.0895 0.8280 0.6660 1.0300 
OTHMAR -0.1001 0.0687 0.1451 0.9050 0.7910 1.0350 
BLACK*MCAID 1.4861 0.3738 0.0380 4.4198 3.6872 9.1958 
 
59 
Table 25 details the interaction effect of Black and Medicaid in the best 
explanatory model, J16.  Black women on Medicaid were twice as likely to have 
radiation therapy as White women not on Medicaid  (OR: 2.95); four times as likely to 
have radiation therapy as White cases on Medicaid (OR: 4.17); and three times as likely 
to have radiation therapy as Black cases  not on Medicaid (OR: 3.19).   
 
Table 25 
Interactive Effect of Black and Medicaid on Model J16 
OR's for Interaction BLACK MCAID BLACK* MCAID  
Black on Medicaid 
compared to -0.0451 -0.3043 1.4861  
White not on Medicaid 0.0000 0.0000 0.0000 Total para. Est. 
Total -0.0451 -0.3043 1.4861 1.1367 
OR 3.1165 95% CI: 1.4978- 6.4840 
     
Black on Medicaid 
compared to -0.0451 -0.3043 1.4861  
White on Medicaid 0.0000 -0.3043 0.0000 Total para. Est. 
Total -0.0451 0.0000 1.4861 1.441 
OR 4.2249 95% CI: 2.0306- 8.7902 
     
Black on Medicaid 
compared to -0.0451 -0.3043 1.4861  
Black not on Medicaid -0.0451 0.0000 0.0000 Total para. Est. 
Total 0.0000 -0.3043 1.4861 1.182 
OR 3.2602 95% CI: 1.5672- 6.7845 
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Discussion and Conclusion 
Breast Conserving Surgery Hypothesis 
Hypothesis One asked if Black women in Florida in 2001 were statistically 
significantly less likely than White women to receive breast conserving surgery rather 
than a mastectomy for treatment of localized breast cancer.  Based on results reviewed in 
the previous chapter the answer to this research question is no.  
The results of statistical analysis of the relationship between Black and Breast 
Conserving Surgery are not significant. The Odds Ratio is 0.823 and the 95% Confidence 
Interval has a range of 0.677-1.000.  Consistent with the literature, age, insurance status, 
rural residence and marital status were significant contributors in the explanation of 
breast conserving surgery use. There were differences between the Black and White 
categories. Of all the local stage breast cancer cases included in the study, Black women 
were more than two times as likely as White women to be less than 50 years of age (OR: 
2.356, 95% CI: 2.143-2.568) and 1.4 times as likely to have Private health insurance  
(OR: 1.421, 95% CI: 1.284-1.555).  When all contributory covariates were included in 
modeling, Black race alone did not improve the explanation of the outcome variable, 
Breast Conserving Surgery. 
Extending insurance coverage to the poor seems to alleviate disparity for 
differences in breast cancer treatment, but clearly Medicaid is not the panacea for all 
diseases.  Poverty as measured by Medicaid status is not associated with Breast 
Conserving Surgery when other variables are controlled for. 
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In terms of the state of Florida’s rate of BCS use as an alternative to Mastectomy 
for local breast cancer, Florida exceeds national geographic variations addressed in the 
Review of the Literature by having a combined Black and White proportion of 66%. 
However, there are incalculable difficulties with examining breast conserving surgery 
versus mastectomy as a quality of cancer care outcome measure. The optimum rate of 
breast conserving therapy use is not 100%. Specifically, surgical treatment as an outcome 
alone focuses on a well-recorded, easily accessible data set that in many ways negates the 
salient and complex series of decisions and processes that precede surgery.  Examples 
include women’s preferences supporting life-style such as a quick versus prolonged 
treatment duration, the role of clinician (especially surgeon) attitude in the decision-
making process, women’s post-surgical satisfaction and peace of mind.  The role of 
patient preference in maintaining high rates of mastectomy has been relatively neglected 
in research (Morrow 2003).  A better measure of quality of care, however difficult to 
obtain, might be to study the degree to which women are being fully informed of their 
surgical treatment options and the degree to which they are involved in the treatment 
decision-making process. 
Radiation Therapy Hypothesis 
Hypothesis Two asked if Black women in Florida were statistically significantly 
less likely than White women to receive radiation therapy after breast conserving surgery.  
Based on results presented in the previous chapter, again the answer is no. 
The results of statistical analysis of the relationship between Black and Radiation 
Therapy use are not significant. The Odds Ratio is 0.9170 and the 95% Confidence 
Interval has a range of 0.7190-1.170.  Consistent with the literature, age, insurance status, 
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rural residence and marital status were significant contributors in the explanation of 
radiation therapy use. There were differences between the Black and White categories.  
When all contributory covariates were included in modeling, Black race alone was not 
necessary as an explanatory variable in the outcome, receipt of Radiation Therapy. 
However, the true number of post-breast conserving surgery cases that actually 
received radiation therapy remains unknown.  As Shavers, Richardson and Button 
reported, there is a drop-off in reporting of cancer care across the continuum of treatment 
such that in this study only 43% of cases received radiation therapy.  Du reported that 
SEER data under recorded radiation therapy use by 26%  (Du  1999). According to FCDS 
statistical analyst and data base manager, Jackie Button, all Radiation Therapy that is 
recorded is listed under one facility number, usually that of the hospital (Button  2004).  
Additionally, radiation treatment facilities are listed by the Florida Cancer Data System 
in a separate Facility Layout that does not match to the Cancer File Layout.  Thus, not 
only is there no mandatory reporting of radiation therapy receipt, in the event that 
treatment is recorded it has no match to patient records, making impossible the ability to 
geocode or to otherwise calculate distance from residence of the patient to treatment 
facility.  
Our findings are consistent with the literature, Black women on Medicaid were 
more likely to receive radiation therapy than those women not insured by Medicaid 
(Bradley 2002).  In order to determine if the statistically significant interaction term 
between Black and Medicaid for receipt of radiation therapy post-breast conserving 
surgery was an artifact of the manner in which data is collected, a separate analysis was 
run that compared Metro to a collapsed Small Metro and Non Metro populations.  There 
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was no statistically significant difference in the results, which reaffirms that Black 
women on Medicaid have the highest rate of radiation therapy use. 
Implications and Recommendations 
While this study adds to the knowledge of the relationship between race and 
breast conserving surgery and radiation therapy use for localized breast cancer, a number 
of limitations should be acknowledged. Consistent with most of the studies in the 
literature, this study presented analysis based on observational rather than experimental 
data. The use of the FCDS dataset made it impossible to fully account for differences in 
patient characteristics that may have effected selection into the various categories of 
covariates. Another of the usual limitations is geographic scope which may be acceptable 
because the region covered is large in elderly population size and important with respect 
to the evolution of geriatric health care. Last, co-morbidity data that may have been 
counter indications to the use of breast conserving surgery and radiation therapy were 
absent so that an unknown number of patients may have been otherwise ineligible for 
inclusion in the study. 
An impressive array of organizations fund Breast Cancer research on a myriad of 
levels. On the national level the leader is the National Cancer Institute followed by the 
National Institutes of Health. There is also the federally funded Department of Defense 
Breast Cancer Research Program. Other national and state level organizations include the 
American Cancer Society, the Susan G. Komen Breast Cancer Research Fund and the 
AVON Breast Cancer Organization.  Each of these organizations should fund research 
that seeks not only to find new and innovative breast cancer cures (treatment) but also to 
fund research that tracks disparities. 
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With breast cancer firmly entrenched on the national research agenda, the policies 
that enable poor and underserved women to access screening and treatment should be 
subjected to further research so that further policy recommendations can be made based 
on Aday’s principles of effectiveness, efficiency and equity  (Aday  2004).  Should the 
NBCCEDP be successfully evaluated as achieving its healthcare system objective, then 
further policy ideas could be generated to expand screening and treatment services to 
other diseases such as colon cancer or prostate cancer. Although those policy 
recommendations may not be received or acted upon immediately, the ideas could 
circulate as research generated alternatives in Kingdon’s policy primeval soup where in 
they can await the confluence of the streams and the opening of a policy window 
(Kingdon 1995).  However, in the absence of further health services research pertaining 
to the expected percentages of appropriate use of breast conserving surgery and radiation 
therapy, it would be unwise to dictate a policy standard such as a HEDIS measure. 
The findings in this study have important implications for policy makers, 
clinicians and researchers that call for and could aid in additional initiatives and studies to 
provide improved understanding of the quality of breast cancer treatment in Florida. 
1. Other variables could have been useful in explaining the relationship between 
the variable of interest and either of the outcomes, breast conserving surgery 
and radiation therapy use. Examples of these that are not collected nor 
included in the FCDS dataset are Body Mass Index (BMI), co-morbidities, 
annual household income, and level of education. 
2. The FCDS should act to counter the severe limitations in the ability to analyze 
the appropriate receipt of radiation therapy after breast conserving surgery. 
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The first is the lack of mandatory reporting requirements by free-standing 
treatment facilities. The second is FCDS failure to include location of 
treatment in the tumor registry. 
3. Research efforts should focus on the impact of patient choice, clinician bias 
and informed consent in the decision making process, and their complex 
relation to mastectomy versus breast conserving therapy use for local stage 
breast cancer. 
4. Researchers and policymakers must continue to observe and monitor trends in 
breast cancer incidence, screening, treatment and mortality in order to 
accurately assess changes and make progress toward diminishing breast 
cancer disparities in all population subgroups. New therapies such as short-
term, intense radiation therapy treatment may make breast conserving therapy 
an acceptable option for rural residence. 
5. Health advocates and health policymakers should take note of the effect of 
Medicaid as a social equalizer for breast cancer treatment specifically through 
the vehicle of the National Breast and Cervical Cancer Early Detection 
Program (NBCCEDP). Future initiatives could seek to provide screening and 
treatment through the Medicaid system for other diseases which could help to 
dramatically eliminate disparities in other areas. 
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Appendices 
Appendix A. Summary of Logistic Regression Models for Breast Conserving Surgery 
Model 
Identity 
Covariates Included BLACK 
par. Est. 
BLACK 
OR 
OR 
95% LL 
OR 
95% 
UL 
BLACK P 
value 
Significant Covariates Neg2LogL df 
A          BLACK -0.1947 0.8230 0.6770 1.0000 0.0506 9166.8580 1
A2          BLACK, MIDAGE, OLDAGE,
VERYOLD 
-0.1805 0.8350 0.6860 1.0160 0.0722 MIDAGE, OLDAGE 9147.4550 4
A3 BLACK, NOIN, MCAID, MCARE -0.1414 0.8680 0.7120 1.0590 0.1624 NOIN, MCAID 9109.7890 4 
A4 BLACK, SINGLE, OTHMAR -0.1514 0.8590 0.7060 1.0470 0.1324 SINGLE, OTHMAR 9154.5590 3 
A6 BLACK, SMETU, NON METRO -0.1997 0.8190 0.6730 0.9960 0.0456 BLACK, NON METRO 9146.8810 3 
A6A BLACK, NON METRO -0.2009 0.8180 0.6730 0.9950 0.0439 BLACK, NON METRO 9146.9200 2 
B BLACK, NON METRO, MIDAGE, 
OLDAGE, VERYOLD 
-0.1865 0.8300 0.6810 1.0110 0.0636 NON METRO, MIDAGE, 
OLDAGE 
9126.4310  5
C BLACK, NON METRO, MIDAGE, 
OLDAGE, VERYOLD, NOIN, 
MCAID, MCARE, SINGLE, 
OTHMAR 
-0.1056 0.9000 0.7360 1.1000 0.3034 NON METRO, MIDAGE, 
OLDAGE, NOIN, MCAID, 
SINGLE, OTHMAR 
9066.0920  10
C3 BLACK, NON METRO, MIDAGE, 
NOIN, MCAID, SINGLE, OTHMAR 
-0.1097 0.8960 0.7340 1.0950 0.2825 NON METRO, NOIN, 
MCAID, SINGLE, 
OTHMAR (MIDAGE IS 
.08) 
9079.9710  7
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Model 
Identity 
Covariates Included BLACK 
par. Est. 
BLACK 
OR 
OR 
95% LL 
OR 
95% UL 
BLACK P 
value 
Significant Covariates Neg2LogL df 
C4 BLACK, NON METRO, MIDAGE, 
OLDAGE, VERYOLD, NOIN, 
MCAID,  SINGLE, OTHMAR 
-0.1064 0.8990 0.7350 1.0990 0.2997 All except BLACK and 
VERYOLD 
9066.7900  9
C5 NON METRO, MIDAGE, OLDAGE, 
VERYOLD, NOIN, MCAID,  
SINGLE, OTHMAR 
xx xx xx xx xx all except VERYOLD and 
OTHMAR barely (0.0573) 
9067.8580  8
C6 BLACK, NON METRO, MIDAGE, 
OLDAGE, VERYOLD, NOIN, 
MCAID,  SINGLE, OTHMAR 
-0.1591 0.8530 0.6920 1.0510 0.1359 NON METRO, MIDAGE, 
OLDAGE, MCAID, 
SINGLE, OTHMAR 
8423.7990  9
C7 BLACK, NON METRO, MIDAGE, 
OLDAGE, VERYOLD, MCAID,  
SINGLE, OTHMAR 
-0.1630 0.8500 0.6890 1.0470 0.1261 All except VERYOLD 8424.3930 8 
C8 BLACK, NON METRO, MIDAGE, 
OLDAGE, VERYOLD, MCAID,  
SINGLE, OTHMAR 
-0.1326 0.8760 0.7170 1.0690 0.1931 All except VERYOLD 9111.5920 8 
C9 NON METRO, MIDAGE, OLDAGE, 
VERYOLD, MCAID,  SINGLE, 
OTHMAR 
xx xx xx xx xx All except VERYOLD 9113.2700 7 
75 
 Appendix B. Comparison of Models for Breast Conserving Surgery 
  Model Black
Covariate diff 
% change in Black 
Covariate 
Neg 2 L Diff Df diff Chisq Notes 
A to A2 -0.0142 0.0729 19.4030 3 0.0002 Age categorical (VERYOLD) better than crude 
A to A3 -0.0533 0.2738 57.0690 3 0.0000 Insurance better than crude, large change in covariate 
A to A4 0.3461 -1.7776 12.2990 2 0.0021 Marital better than crude, large change in covariate 
A to A6 0.0050 -0.0257 19.9770 2 0.0000 USDA better than crude 
A to A6A 0.0062 -0.0318 19.9380 1 0.0000 Just NON METRO better than crude 
A6 to A6A 0.0012 -0.0060 0.0390 1 0.8434 Model same with or without SMETU 
A6A to B -0.0144 0.0717 20.4890 3 0.0001 Adding age category (VERYOLD) to a model with BLACK and 
NON METRO improves fit.  Medium change in covariate. 
A2 to B 0.0060 -0.0332 21.0240 1 0.0000 Adding NON METRO to a model with age category 
(VERYOLD) and BLACK improves fit. 
A2 to C -0.0749 0.4150 81.3630 6 0.0000 Adding all insurance and marital to age category (VERYOLD) 
and BLACK improves fit.  Large change in covariate 
A3 to C -0.0358 0.2532 43.6970 6 0.0000 Adding age category (VERYOLD) to all insurance and all marital 
improves fit.  Large change in covariate. 
A4 to C -0.0458 0.3025 88.4670 7 0.0000 Adding insurance, Non Metroity and age catgory (VERYOLD) 
improves the fit of a model with just BLACK and marital in it. 
A6A to C -0.0953 0.4744 80.8280 8 0.0000 Age cat (VERYOLD), all insurance, and marital improve the fit 
of a model with only BLACK and NON METRO in it. 
B to C -0.0809 0.4338 60.3390 5 0.0000 Adding insurance and marital improves the model with just age 
category (VERYOLD), NON METRO, BLACK. 
C4 to C -0.0008 0.0075 0.6980 1 0.4035 MEDICARE makes no difference in the C model 
C8 to C4 -0.0262 0.1976 44.8020 1 0.0000 It is better to exclude NOIN from model. 
C9 to C8 xx xx 1.6780 1 0.1952 BLACK makes no difference in the C8 model. 
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 Appendix C. Results of Interaction Term Modeling for Hypothesis One. 
Model 
Identity 
Covariates Included Notes 
J1 BLACK, NON METRO, MIDAGE, OLDAGE, VERYOLD, MCAID, SINGLE, OTHMAR, 
BLACK*MCAID 
interaction not significant (p= 0.5213) 
J2 BLACK, NON METRO, MIDAGE, OLDAGE, VERYOLD, MCAID, SINGLE, OTHMAR, 
BLACK*SINGLE, BLACK*OTHMAR 
interaction not significant (p=  0.5800,  
0.8302) 
J3 BLACK, NON METRO, MIDAGE, OLDAGE, VERYOLD, MCAID, SINGLE, OTHMAR, 
BLACK*NON METRO 
interaction not significant (p=0.4141) 
J4 BLACK, NON METRO, MIDAGE, OLDAGE, VERYOLD, MCAID, SINGLE, OTHMAR, 
BLACK*MIDAGE, BLACK*OLDAGE, BLACK*VERYOLD 
interaction not significant (p=   0.8994,   
0.9209,    0.2575) 
J5 BLACK, NON METRO, AGE, MCAID, SINGLE, OTHMAR, BLACK*AGE interaction not significant (p= 0.8607) 
J6 BLACK, NON METRO, MIDAGE, OLDAGE, VERYOLD, MCAID, SINGLE, OTHMAR, NON 
METRO*MIDAGE, NON METRO*OLDAGE, NON METRO*VERYOLD 
interaction not significant (p=   0.8215,  
0.6184,  0.4965) 
J7 BLACK, NON METRO, MIDAGE, OLDAGE, VERYOLD, MCAID, SINGLE, OTHMAR, NON 
METRO*SINGLE, NON METRO*OTHMAR 
interaction not significant (p= 0.8047,   
0.5991) 
J8 BLACK, NON METRO, MIDAGE, OLDAGE, VERYOLD, MCAID, SINGLE, OTHMAR, 
MIDAGE*SINGLE, OLDAGE*SINGLE, VERYOLD*SINGLE, MIDAGE*OTHMAR, 
OLDAGE*OTHMAR, VERYOLD*OTHMAR 
interaction not significant (p=0.7644, 
0.2605, 0.1547, 0.3366, 0.7362, 0.5986) 
J9 BLACK, NON METRO, MIDAGE, OLDAGE, VERYOLD, MCAID, SINGLE, OTHMAR, NON 
METRO*MIDAGE, NON METRO*OLDAGE, NON METRO*VERYOLD, NON METRO*SINGLE, 
NON METRO*OTHMAR, SINGLE*MIDAGE, SINGLE*OLDAGE, SINGLE*VERYOLD, 
OTHMAR*MIDAGE, OTHMAR*OLDAGE, OTHMAR*VERYOLD, NON 
METRO*SINGLE*MIDAGE, NON METRO*SINGLE*OLDAGE, NON 
METRO*SINGLE*VERYOLD, NON METRO*OTHMAR*MIDAGE, NON 
METRO*OTHMAR*OLDAGE, NON METRO*OTHMAR*VERYOLD 
interactions not significant (p=0.7880, 
0.8435, 0.9238, 0.5861, 0.2621, 0.6146, 
0.2824, 0.1555, 0.3781, 0.9209, 0.4542, 
0.3855, 0.7655, 0.9076, 0.8238, 0.2454, 
0.2355) 
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Appendix C. (Continued) 
Model 
Identity 
Covariates Included Notes 
J10 BLACK NON METRO MIDAGE OLDAGE VERYOLD MCAID SINGLE OTHMAR BLACK*NON 
METRO BLACK*MCAID NON METRO*MCAID BLACK*NON METRO*MCAID 
interactions not significant (p=0.3058, 
0.5295, 0.5028, 0.7954) 
J11 BLACK NON METRO MIDAGE OLDAGE VERYOLD MCAID SINGLE OTHMAR NON 
METRO*MIDAGE NON METRO*OLDAGE NON METRO*VERYOLD NON METRO*SINGLE 
NON METRO*OTHMAR SINGLE*MIDAGE SINGLE*OLDAGE SINGLE*VERYOLD 
OTHMAR*MIDAGE OTHMAR*OLDAGE OTHMAR*VERYOLD NON 
METRO*SINGLE*MIDAGE NON METRO*SINGLE*OLDAGE NON 
METRO*SINGLE*VERYOLD NON METRO*OTHMAR*MIDAGE NON 
METRO*OTHMAR*OLDAGE NON METRO*OTHMAR*VERYOLDNON 
METRO*MIDAGE*SINGLE NON METRO*MIDAGE*OTHMAR NON 
METRO*OLDAGE*SINGLE NON METRO*OLDAGE*OTHMAR NON 
METRO*VERYOLD*SINGLE NON METRO*VERYOLD*OTHMAR 
interactions not significant (p=0.7880,  
0.8435,  0.9238,  0.5861,  0.2621,  0.6146,  
0.2824,  0.1555,  0.3781,  0.9209,  0.4542,  
0.3855,  0.7655,  0.9076,  0.8238,  0.2454,  
0.2355) 
J12 BLACK NON METRO MIDAGE OLDAGE VERYOLD MCAID SINGLE OTHMAR 
BLACK*MIDAGE BLACK*OLDAGE BLACK*VERYOLD BLACK*SINGLE BLACK*OTHMAR 
MIDAGE*SINGLE MIDAGE*OTHMAR OLDAGE*SINGLE OLDAGE*OTHMAR 
VERYOLD*SINGLE VERYOLD*OTHMAR BLACK*MIDAGE*SINGLE 
BLACK*MIDAGE*OTHMAR BLACK*OLDAGE*SINGLE BLACK*OLDAGE*OTHMAR 
BLACK*VERYOLD*SINGLE BLACK*VERYOLD*OTHMAR 
interactions not significant (p=0.9473,  
0.5772,  0.6388,  0.8363,  0.5177,  0.8070,  
0.2843,  0.2988,  0.9497,  0.1265,  0.4491,  
0.9531,  0.6908,  0.8849,  0.3911,  0.3887,  
0.6801) 
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 Appendix D. Summary of Logistic Regression for Receipt of Radiation Therapy 
Model 
Identity 
Covariates Included BLACK 
par. Est. 
BLACK 
OR 
OR 
95% LL 
OR 95% 
UL 
BLACK P 
value 
Significant Covariates Neg2LogL df 
A          BLACK -0.0866 0.9170 0.7190 1.1700 0.4856 6496.9150 1
A1 BLACK, AGE -0.0771 0.9260 0.7250 1.1830 0.5376   6496.4980 2 
A2          BLACK, MIDAGE, OLDAGE,
VERYOLD 
-0.0577 0.9440 0.7380 1.2070 0.6456 MIDAGE, OLDAGE 6445.0810 4
A3 BLACK, NOIN, MCAID, MCARE -0.0582 0.9430 0.7380 1.2060 0.6420   6492.3670 4 
A4 BLACK, SINGLE, OTHMAR -0.0436 0.9570 0.7490 1.2240 0.7280 SINGLE, OTHMAR 6487.4880 3 
A6 BLACK, SMETU, NON METRO -0.3751 0.9500 0.7440 1.2140 0.6821 SMETU highly sig, 
NON METRO close (p= 
0.0801) 
6456.3190  3
A6A BLACK, NON METRO -0.0945 0.9100 0.7130 1.1610 0.4470 NON METRO 6489.0040 2 
B BLACK, NON METRO, MIDAGE, 
OLDAGE, VERYOLD 
-0.0659        0.9360 0.7320 1.1980 0.5999 NON METRO,
MIDAGE, OLDAGE 
6435.9530 5
C BLACK, NON METRO, MIDAGE, 
OLDAGE, VERYOLD, NOIN, MCAID, 
MCARE, SINGLE, OTHMAR 
-0.0239        0.9760 0.7610 1.2530 0.8514 NON METRO,
OLDAGE, VERYOLD, 
SINGLE 
6428.4930 10
C3 BLACK, NON METRO, MIDAGE, 
NOIN, MCAID, SINGLE, OTHMAR 
-0.0434        0.9580 0.7480 1.2260 0.7312 NON METRO,
SINGLE, OTHMAR 
6475.9230 7
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Appendix D. (Continued) 
Model 
Identity 
Covariates Included BLACK 
par. Est. 
BLACK 
OR 
OR 
95% LL 
OR 95% 
UL 
BLACK P 
value 
Significant Covariates Neg2LogL df 
C4 BLACK, NON METRO, MIDAGE, 
OLDAGE, VERYOLD, NOIN, 
MCAID,  SINGLE, OTHMAR 
-0.0227 0.9780 0.7620 1.2550 0.8584 NON METRO, MIDAGE, 
OLDAGE 
6429.0240  9
C5 NON METRO, MIDAGE, OLDAGE, 
VERYOLD, NOIN, MCAID,  SINGLE, 
OTHMAR 
XX XX XX XX XX NON METRO, MIDAGE, 
OLDAGE 
6429.0560  8
C6 BLACK, NON METRO, MIDAGE, 
OLDAGE, VERYOLD, NOIN, 
MCAID,  SINGLE, OTHMAR 
-0.0097 0.9900 0.7640 1.2840 0.9415 NON METRO, MIDAGE, 
OLDAGE, SINGLE, 
OTHMAR 
6061.0090  9
C7 BLACK, NON METRO, MIDAGE, 
OLDAGE, VERYOLD, MCAID,  
SINGLE, OTHMAR 
-0.0154 0.9850 0.7600 1.2760 0.9074 NON METRO, MIDAGE, 
OLDAGE, SINGLE 
6061.9960  8
C8 BLACK, NON METRO, MIDAGE, 
OLDAGE, VERYOLD, MCAID,  
SINGLE, OTHMAR 
-0.0315 0.9690 0.7550 1.2430 0.8044 NON METRO, MIDAGE, 
OLDAGE, SINGLE, 
OTHMAR 
6430.3970  8
C9 NON METRO, MIDAGE, OLDAGE, 
VERYOLD, MCAID,  SINGLE, 
OTHMAR 
XX XX XX XX XX NON METRO, MIDAGE, 
OLDAGE, SINGLE 
6430.4580  7
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Model 
Identity 
Covariates Included BLACK 
par. Est. 
BLACK 
OR 
OR 
95% LL 
OR 
95% 
UL 
BLACK 
P value 
Significant Covariates Neg2LogL df 
C10 BLACK MIDAGE OLDAGE 
VERYOLD MCAID SMETU NON 
METRO SINGLE OTHMAR 
0.0072        1.0070 0.7840 1.2930 0.9551 MIDAGE, OLDAGE,
SMETU, NON METRO 
(SINGLE IS CLOSE AT  
0.0915) 
6402.0040 9
J15 BLACK MIDAGE OLDAGE 
VERYOLD MCAID SMETU NON 
METRO BLACK*MCAID 
XX XX XX XX XX MIDAGE, OLDAGE SMETU 
NON METRO BLACK* 
MCAID 
6401.6970  8
J16 BLACK MIDAGE OLDAGE 
VERYOLD MCAID SMETU NON 
METRO SINGLE OTHMAR 
BLACK*MCAID 
XX XX XX XX XX MIDAGE, OLDAGE SMETU 
NON METRO BLACK* 
MCAID (SINGLE IS CLOSE 
AT  0.0895) 
6397.4190  10
J18 BLACK MIDAGE OLDAGE 
VERYOLD MCAID SMETU NON 
METRO SINGLE BLACK*MCAID 
XX XX XX XX XX MIDAGE, OLDAGE SMETU 
NON METRO BLACK* 
MCAID 
6399.5440  9
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Model 
Identity 
Covariates Included BLACK 
par. Est. 
BLACK 
OR 
OR 
95% 
LL 
OR 
95% 
UL 
BLACK P 
value 
Significant Covariates Neg2LogL df 
J19 BLACK MIDAGE OLDAGE VERYOLD 
MCAID SMETU NON METRO OTHMAR 
BLACK*MCAID 
XX        XX XX XX XX MIDAGE, OLDAGE
SMETU NON METRO 
BLACK* MCAID 
6400.3280 9
J20 BLACK MIDAGE OLDAGE VERYOLD 
MCAID SMETU NON METRO SINGLE 
OTHMAR BLACK*MCAID 
XX        XX XX XX XX MIDAGE, OLDAGE
SMETU  BLACK* 
MCAID 
6024.1040 10
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Appendix E. Comparison of Models for Receipt of Radiation Therapy 
Model Black Covariate diff % change in Black Covariate Neg 2 L Diff Df diff Chisq 
A to A1 -0.0095 0.1097 0.4170 1 0.5184 
A to A2 -0.0289 0.3337 51.8340 3 0.0000 
A to A3 -0.0284 0.3279 4.5480 3 0.2080 
A to A4 0.1302 -1.5035 9.4270 2 0.0090 
A to A5 0.0202 -0.2333 10.6430 1 0.0011 
A to A6 0.2885 -3.3314 40.5960 2 0.0000 
A to A6A 0.0079 -0.0912 7.9110 1 0.0049 
A6 to A6A -0.2806 0.7481 32.6850 1 0.0000 
A6A to B -0.0286 0.3026 53.0510 3 0.0000 
A2 to B 0.0082 -0.1421 9.1280 1 0.0025 
A6A to B1 0.4168 -4.4106 14.7130 2 0.0006 
A2 to C -0.0338 0.5858 16.5880 6 0.0109 
A3 to C -0.0343 0.5893 63.8740 6 0.0000 
A4 to C -0.0197 0.4518 58.9950 7 0.0000 
A6A to C -0.0706 0.7471 60.5110 8 0.0000 
B to C -0.0420 0.6373 7.4600 5 0.1886 
A3 to C1 -0.0557 0.9577 30.1820 5 0.0000 
A4 to C1 -0.0411 0.9436 25.3030 6 0.0003 
A6A to C1 -0.0920 0.9740 26.8190 7 0.0004 
B1 to C1 -0.5088 0.9952 12.1060 5 0.0334 
C4 to C 0.0012 -0.0529 0.5310 1 0.4662 
C8 to C4 -0.0088 0.2794 1.3730 1 0.2413 
C9 to C8 xx xx 0.0610 1 0.8049 
C10 to J16 xx xx 4.5850 1 0.0323 
J15 to J16 xx xx 4.2780 2 0.1178 
J18 to J16 xx xx 2.1250 1 0.1449 
J19 to J16 xx xx 2.9090 1 0.0881 
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Appendix F. Results of Interaction Term Modeling for Breast Conserving Surgery Population. 
Model 
Identity 
Covariates Included Notes 
J1 BLACK, NON METRO, MIDAGE, OLDAGE, VERYOLD, 
MCAID, SINGLE, OTHMAR, BLACK*MCAID 
interaction significant (p=  0.0384) 
J2 BLACK, NON METRO, MIDAGE, OLDAGE, VERYOLD, 
MCAID, SINGLE, OTHMAR, BLACK*SINGLE, 
BLACK*OTHMAR 
interaction not significant (p=0.2970, 0.8458) 
J3 BLACK, NON METRO, MIDAGE, OLDAGE, VERYOLD, 
MCAID, SINGLE, OTHMAR, BLACK*NON METRO 
interaction not significant (p=  0.9366) 
J4 BLACK, NON METRO, MIDAGE, OLDAGE, VERYOLD, 
MCAID, SINGLE, OTHMAR, BLACK*MIDAGE, 
BLACK*OLDAGE, BLACK*VERYOLD 
significance of interaction debatable (p=0.5031, 0.1947, 0.0755) 
J5 BLACK, NON METRO, AGE, MCAID, SINGLE, OTHMAR, 
BLACK*AGE 
significance of interaction debatable (p=  0.1855) 
J6 BLACK, NON METRO, MIDAGE, OLDAGE, VERYOLD, 
MCAID, SINGLE, OTHMAR, NON METRO*MIDAGE, NON 
METRO*OLDAGE, NON METRO*VERYOLD 
interaction not significant (p=0.8467, 0.7225, 0.2678) 
J7 BLACK, NON METRO, MIDAGE, OLDAGE, VERYOLD, 
MCAID, SINGLE, OTHMAR, NON METRO*SINGLE, NON 
METRO*OTHMAR 
interaction not signficant (p=0.6892, 0.9522) 
J8 BLACK, NON METRO, MIDAGE, OLDAGE, VERYOLD, 
MCAID, SINGLE, OTHMAR, MIDAGE*SINGLE, 
OLDAGE*SINGLE, VERYOLD*SINGLE, MIDAGE*OTHMAR, 
OLDAGE*OTHMAR, VERYOLD*OTHMAR 
interaction not significant (p=0.2091, 0.1851, 0.2944, 0.7146, 0.9508, 
0.9901) 
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J9 BLACK, NON METRO, MIDAGE, OLDAGE, VERYOLD, 
MCAID, SINGLE, OTHMAR, NON METRO*MIDAGE, NON 
METRO*OLDAGE, NON METRO*VERYOLD, NON 
METRO*SINGLE, NON METRO*OTHMAR, SINGLE*MIDAGE, 
SINGLE*OLDAGE, SINGLE*VERYOLD, OTHMAR*MIDAGE, 
OTHMAR*OLDAGE, OTHMAR*VERYOLD, NON 
METRO*SINGLE*MIDAGE, NON METRO*SINGLE*OLDAGE, 
NON METRO*SINGLE*VERYOLD, NON 
METRO*OTHMAR*MIDAGE, NON 
METRO*OTHMAR*OLDAGE, NON 
METRO*OTHMAR*VERYOLD 
interaction not significant (p=0.5599, 0.5893, 0.1738, 0.4946, 0.9543, 
0.1946, 0.1482, 0.2736, 0.4871, 0.7053, 0.7313, 0.7143, 0.4182, 
0.9846, 0.9533, 0.9536, 0.9515) 
J10 BLACK NON METRO MIDAGE OLDAGE VERYOLD MCAID 
SINGLE OTHMAR BLACK*NON METRO BLACK*MCAID NON 
METRO*MCAID BLACK*NON METRO*MCAID 
interaction between BLACK and MCAID interesting, but whole 
model is not significant (p=0.9306, 0.0391, 0.7144, 0.6676) 
J11 BLACK NON METRO MIDAGE OLDAGE VERYOLD MCAID 
SINGLE OTHMAR NON METRO*MIDAGE NON 
METRO*OLDAGE NON METRO*VERYOLD NON 
METRO*SINGLE NON METRO*OTHMAR SINGLE*MIDAGE 
SINGLE*OLDAGE SINGLE*VERYOLD OTHMAR*MIDAGE 
OTHMAR*OLDAGE OTHMAR*VERYOLD NON 
METRO*SINGLE*MIDAGE NON METRO*SINGLE*OLDAGE 
NON METRO*SINGLE*VERYOLD NON 
METRO*OTHMAR*MIDAGE NON 
METRO*OTHMAR*OLDAGE NON 
METRO*OTHMAR*VERYOLDNON METRO*MIDAGE*SINGLE 
NON METRO*MIDAGE*OTHMAR NON 
METRO*OLDAGE*SINGLE NON METRO*OLDAGE*OTHMAR 
NON METRO*VERYOLD*SINGLE NON 
METRO*VERYOLD*OTHMAR 
interaction not significant (p=0.5599, 0.5893, 0.1738, 0.4946, 0.9543, 
0.1946, 0.1482, 0.2736, 0.4871, 0.7053, 0.7313, 0.7143, 0.4182, 
0.9846, 0.9533, 0.9536, 0.9515) 
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86 
J12 BLACK NON METRO MIDAGE OLDAGE VERYOLD MCAID 
SINGLE OTHMAR BLACK*MIDAGE BLACK*OLDAGE 
BLACK*VERYOLD BLACK*SINGLE BLACK*OTHMAR 
MIDAGE*SINGLE MIDAGE*OTHMAR OLDAGE*SINGLE 
OLDAGE*OTHMAR VERYOLD*SINGLE VERYOLD*OTHMAR 
BLACK*MIDAGE*SINGLE BLACK*MIDAGE*OTHMAR 
BLACK*OLDAGE*SINGLE BLACK*OLDAGE*OTHMAR 
BLACK*VERYOLD*SINGLE BLACK*VERYOLD*OTHMAR 
interaction not significant (p=0.9052, 0.9718, 0.9645, 0.1697, 0.8731, 
0.5617, 0.6364, 0.5831, 0.9742, 0.4248, 0.9667, 0.3551, 0.6002, 
0.1902, 0.7275, 0.9655, 0.9676) 
J13 BLACK NOIN MCAID MCARE BLACK*NOIN BLACK*MCAID 
BLACK*MCARE 
interaction compelling, especially for MCAID (p=0.2508, 0.0473, 
0.2814) 
J15 BLACK MIDAGE OLDAGE VERYOLD MCAID SMETU NON 
METRO BLACK*MCAID 
interaction significant (p= 0.0356), overall better than J14 
J16 BLACK MIDAGE OLDAGE VERYOLD MCAID SMETU NON 
METRO SINGLE OTHMAR BLACK*MCAID 
interaction significant (p=  0.0380), single and othmar may contribute 
to model. 
J17 BLACK MIDAGE OLDAGE VERYOLD MCAID SMETU NON 
METRO SINGLE OTHMAR BLACK*MCAID BLACK*SINGLE 
BLACK*OTHMAR SINGLE*MCAID OTHMAR*MCAID 
BLACK*MCAID*SINGLE BLACK*MCAID*OTHMAR 
Interactions not significnant (p=0.4454, 0.3418, 0.8943, 0.4037, 
0.3621, 0.7381, 0.9521) 
J18 BLACK MIDAGE OLDAGE VERYOLD MCAID SMETU NON 
METRO SINGLE BLACK*MCAID 
J16 with just SINGLE. Interaction significant (p= 0.0343),  
J19 BLACK MIDAGE OLDAGE VERYOLD MCAID SMETU NON 
METRO OTHMAR BLACK*MCAID 
J16 with just OTHMAR. Interaction significant (p= 0.0387),  
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